
North East London (NEL) Management of Infection Guidance for Primary Care

Adapted from the Public Health England (PHE) and National Institute for Health and Care Excellence (NICE) Management of infection guidance. For primary care for use across the East London Health and Care Partnership (ELHCP)



These guidelines have been developed in collaboration with:

* Barking, Havering and Redbridge University NHS Trust (BHRuT) Microbiology team
* Barts Health NHS Trust Microbiology teams
* Homerton University Hospital NHS Foundation Trust Microbiology team (HUHFT)
* NHS North East London Foundation NHS Trust (NELFT)
* NHS East London Foundation Trust (ELFT)
* NHS Barking and Dagenham, NHS Havering and NHS Redbridge (BHR) Clinical Commissioning Groups (CCGs)
* NHS City and Hackney (C&H) CCG
* NHS Newham CCG
* NHS Tower Hamlets CCG
* NHS Waltham Forest CCG


The guideline review group has involved a range of healthcare professionals including GPs, Microbiologists/Infectious disease consultants, Primary Care Pharmacists, Prescribing Advisors, and Antimicrobial Pharmacists. Advice has also been sought from local dermatologists, obstetricians and gastroenterologists where appropriate.

The development and maintenance of this guideline is a key function of the North East London Antimicrobial Resistance Strategy Group (NEL AMRSG), which is a local collaboration of health and social care partners.

*https://asweknowitlife.wordpress.com/2012/12/04/antibiotic-resistance-cycle/*

Updated: October 2020

Date of review: October 2021, or sooner if required  
Version: 1.2

Contents

|  |  |
| --- | --- |
|  | **Page No.** |
| [Guideline Statement, Aims and Objectives](#_Aims_and_Objectives) | 3 |
| [Antimicrobial Prescribing Guidance / Treating Penicillin-Allergic Patients](#_Antimicrobial_prescribing_guidance) | 4 |
| [**Upper respiratory tract infections**](#UpperRTI) | 5 |
| [**Lower respiratory tract infections**](#LowerRTI) | 7 |
| [**Urinary tract infections**](#UTI) | 12 |
| [**Meningitis**](#Meningitis) | 17 |
| [**Gastrointestinal tract infections**](#GI) | 17 |
| [**Genital tract infections**](#Genital) | 20 |
| [**Skin and soft tissue infections**](#Skin) | 23 |
| [**Eye Infections**](#Eye) | 30 |
| [**Suspected dental infections (outside dental settings)**](#Dental) | 30 |
| [Information for Patients](#Information) | 32 |
| [Notification for Diseases](#NotofDisease) | 35 |
| [Other References and Useful Links](#Refother) | 36 |
| [Key Contacts and Guideline Review Group](#KeyContacts) | 37 |
| [Document Version Control](#VersionControl) | 38 |

|  |  |
| --- | --- |
| **Organisations who have adopted this document** | **Date ratified by organisation** |
| NHS Barking and Dagenham, NHS Havering and NHS Redbridge (BHR) Clinical Commissioning Groups |  |
| NHS Waltham Forest, NHS Newham, and NHS Tower Hamlets (WEL) Clinical Commissioning Groups | 28th October 2020 |
| NHS City and Hackney (C&H) Clinical Commissioning Group |  |
| \*Endorsed by North East London Antimicrobial Resistance Strategy Group (NEL AMRSG) | 28th October 2020\* |

**Guideline Statement**

These guidelines are to be read in conjunction with current guidance from NICE and PHE, other national bodies (e.g. BASHH – British Association for Sexual Health and HIV), relevant NICE Clinical Knowledge Summaries (CKS) and resources from the [RCGP TARGET Toolkit](https://www.rcgp.org.uk/TARGETantibiotics/). Evidence-based antimicrobial prescribing is essential to begin to address the challenge of increasingly antibiotic-resistant bacteria, and the rise in health care acquired infections. The Health and Social Care Act 2008 (updated 2011) introduces the Code of Practice for the Prevention and Control of HealthCare Associated Infections, also known as the Hygiene Code. This Code requires all health care organisations to have a policy in place on antimicrobial prescribing, in order to reduce the incidence and prevalence of Health Care Associated Infections (HCAI). Where possible, treatment is based on national guidance (Public Health England: Management of infection guidance for primary care for consultation and local adaptation). Local adaptation has been applied where required on advice of the local acute trusts department of infection, based on local sensitivities and resistance patterns.

Infections account for a large proportion of the acute workload seen in general practice and cause considerable patient distress. The prescriber is sometimes put under pressure to prescribe by patients who perceive that antibiotics will provide quick resolution, particularly if they are under pressure to return to work.

However, the evidence to support antibiotic treatment is often weak or lacking, and certain illnesses can be self-limiting. Good communication between the prescriber and patient, with adequate time given to the consultation, is known to bring about more selective and appropriate prescribing

# Aims and Objectives of the Guidance

The aims are to:

* Support the rational, safe and cost-effective use of antibiotics by selecting the best approach to managing common infections from the evidence available.
* Promote the selective use of antibiotics to reduce the emergence of antimicrobial resistance in the community.
* Empower patients with information and support mechanisms so they can cope with their infection.

The objectives are to:

* Assist prescribers in managing individuals with infections by providing clear information on the likely clinical outcome with or without treatment and to indicate possible risk.
* Help the prescriber decide whether or not antibiotic treatment is indicated and which antibiotic is the most appropriate.

**This guidance should always be applied in conjunction with clinical judgement and consideration of important individual case factors including allergy, pregnancy, drug interactions and drug safety advice from the MHRA. The recommendations apply only in the absence of contra- indications. Please refer to the latest BNF, BNFc or Summary of Product Characteristics (SmPC) for further information**



# Antimicrobial prescribing guidance – managing common infections

* For all PHE guidance, follow [PHE’s principles of treatment](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care)
* See BNF for appropriate use and dosing in specific populations, for example, hepatic impairment, renal impairment, pregnancy and breastfeeding.

|  |  |  |
| --- | --- | --- |
| **Key** | **Thumnail of BNF for children**Thumnail of visual summary prescribing table | **Click symbols to access doses for children** |
| **Thumnail of visual summary** | **Click to access NICE’s printable visual summary** |

The strength of each PHE recommendation is qualified by a letter in parenthesis. This is an altered version of the grading recommendation system used by [SIGN](http://www.sign.ac.uk/)

|  |  |
| --- | --- |
| **STUDY DESIGN** | **RECOMMENDATION GRADE** |
| Good recent systematic review and meta-analysis of studies | A+ |
| One or more rigorous studies; randomised controlled trials | A- |
| One or more prospective studies | B+ |
| One or more retrospective studies | B- |
| Non-analytic studies, for example case reports or case series | C |
| Formal combination of expert opinion | D |

**Abbreviations**


BD, twice a day; eGFR, estimated glomerular filtration rate; IM, intramuscular; IV, intravenous; MALToma, mucosa-associated lymphoid tissue lymphoma; m/r, modified release; MRSA, methicillin-resistant Staphylococcus aureus; MSM, men who have sex with men; stat, given immediately; OD, once daily; TDS, 3 times a day; QDS, 4 times a day.

| Infection | | Key points | Medicine | Doses | | Length | Visual summary |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Adult | Child |
| Upper respiratory tract infections | | | | | | | |
| Acute sore throat  NICE logo  Public Health England  Last updated:  Jan 2018 | | Advise paracetamol, or if preferred and suitable, ibuprofen for pain.  OTC Medicated lozenges may help pain in adults.  Use [**FeverPAIN**](https://www.nice.org.uk/guidance/ng84/chapter/Terms-used-in-the-guideline) **or** [**Centor**](https://www.nice.org.uk/guidance/ng84/chapter/Terms-used-in-the-guideline) to assess symptoms:  FeverPAIN 0-1 or Centor 0-2: no antibiotic; FeverPAIN 2-3: no or back-up antibiotic; FeverPAIN 4-5 or Centor 3-4: immediate or back-up antibiotic.  Systemically very unwell or high risk of complications: immediate antibiotic.  Avoid broader-spectrum penicillins (e.g. amoxicillin) for the empirical treatment of sore throat.  For detailed information click the visual summary icon. | First choice: **phenoxymethylpenicillin** | 500mg QDS or  1000mg BD | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng84/resources/visual-summary-pdf-4723226606) | 5 to 10 days | [Link to visual summary](https://www.nice.org.uk/guidance/ng84/resources/visual-summary-pdf-4723226606) |
| Penicillin allergy:  **clarithromycin** OR | 250mg to 500mg BD | 5 days |
| **erythromycin** (preferred if pregnant)  (**erythromycin** or **clarithromycin** only needed for 5 days as they have a broader spectrum of activity than **phenoxymethylpenicillin** and more likely to drive bacterial resistance) | 250mg to 500mg QDS or  500mg to 1000mg BD | 5 days |
| Influenza  Public Health England  Last updated:  Feb 2019 | | Annual vaccination is essential for all those ‘at risk’ of influenza.1D Antivirals are not recommended for healthy adults.1D,2A+ Treat ‘at risk’ patients with 5 days oseltamivir 75mg BD,1D when influenza is circulating in the community, and ideally within 48 hours of onset (36 hours for zanamivir treatment in children),1D,3D or in a care home where influenza is likely.1D,2A+  At risk: [pregnant](http://www.uktis.org/) (and up to 2 weeks post-partum); children under 6 months; adults 65 years or older; chronic respiratory disease (including COPD and asthma); significant cardiovascular disease (not hypertension); severe immunosuppression; chronic neurological, renal or liver disease; diabetes mellitus; morbid obesity (BMI>40).4D See the [PHE Influenza](https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents) guidance for the treatment of patients under 13 years.4D In severe immunosuppression, or oseltamivir resistance, use zanamivir 10mg BD5A+,6A+ (2 inhalations twice daily by diskhaler for up to 10 days) and seek advice.4D  Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care). | | | | | |
| Scarlet fever (GAS)  Public Health England  Last updated:  Oct 2018  NICE CKS update Mar 2020 | | Prompt treatment with appropriate antibiotics significantly reduces the risk of complications.1D Vulnerable individuals (immunocompromised, the comorbid, or those with skin disease) are at increased risk of developing complications.1D | **Phenoxymethylpenicillin** 2D | 500mg QDS2D | [Link to BNF for children](https://cks.nice.org.uk/topics/scarlet-fever/management/management/) | 10 days3A+,4A+,5A+ | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| Penicillin allergy:  **Azithromycin** | 500mg OD | [Link to BNF for children](https://cks.nice.org.uk/topics/scarlet-fever/management/management/) | 5 days (NICE) |
| Optimise analgesia2D and give safety netting advice | | | |
| Scarlet fever is a [notifiable disease](https://www.gov.uk/government/collections/notifications-of-infectious-diseases-noids), health professionals must inform local health protection teams of suspected cases.  **North East and North Central London Health Protection Team (NENCLHPT) numbers:**   * Daytime Tel: **020 3837 7084 (option 2)** * **For Out of Hours Advice**: Tel: **0151 909 1215** (between 5pm and 9am and during weekends and Bank Holidays) * Email: [necl.team@phe.gov.uk](mailto:necl.team@phe.gov.uk) ; [phe.nenclhpt@nhs.net](mailto:phe.nenclhpt@nhs.net) | | | | | |
| Acute otitis media  NICE logo  Public Health England  Last updated: Feb 2018 | | Regular paracetamol or ibuprofen for pain (right dose for age or weight at the right time and maximum doses for severe pain).  Otorrhoea or under 2 years with infection in both ears: no, back-up or immediate antibiotic.  Otherwise: no or back-up antibiotic.  Systemically very unwell or high risk of complications: immediate antibiotic.  For detailed information click on the visual summary. | First choice: **amoxicillin** | - | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng91/resources/visual-summary-pdf-4787282702) | 5 to 7 days | [Link to visual summary](https://www.nice.org.uk/guidance/ng91/resources/visual-summary-pdf-4787282702) |
| Penicillin allergy: **clarithromycin** OR | - | 5 to 7 days |
| **erythromycin** (preferred if pregnant) | - |
| Second choice:  **co-amoxiclav** | - | 5 to 7 days |
| Acute otitis externa  Public Health England  Last updated:  Nov 2017 | | First line: analgesia for pain relief,1D,2D and apply localised heat (such as a warm flannel).2D  Second line: OTC topical acetic acid (>12yrs) e.g. EarCalm spray OR topical antibiotic +/- steroid e.g. betamethasone 0.1% neomycin (Betnesol N drops) or Otomize Spray: similar cure at 7 days.2D,3A+,4B-  If cellulitis or disease extends outside ear canal, or systemic signs of infection, swab ear, start oral flucloxacillin and refer to exclude malignant otitis externa.1D | Second line:  OTC (>12yrs) topical **acetic acid** 2%2D,4B- OR | 1 spray TDS5A- | [Link to BNF for children](https://bnfc.nice.org.uk/treatment-summary/ear.html) | 7 days5A | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| topical **neomycin sulphate** with corticosteroid2D,5A-  (consider safety issues if perforated tympanic membrane)6B- | 3 drops TDS5A- | [Link to BNF for children](https://bnfc.nice.org.uk/drug/neomycin-sulfate.html) | 7 days (min) to  14 days (max)3A+ |
| If cellulitis: **flucloxacillin**7B+ | 250mg QDS2D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/flucloxacillin.html) | 7 days2D |
| If severe: 500mg QDS2D |
| Sinusitis  NICE logo  Public Health England  Last updated:  Oct 2017 | | Advise OTC paracetamol or ibuprofen for pain. Little evidence that nasal saline or nasal decongestants help, but people may want to try them OTC.  Symptoms for 10 days or less: no antibiotic.  Symptoms with no improvement for more than 10 days: no antibiotic or back-up antibiotic depending on likelihood of bacterial cause.  Consider high-dose nasal corticosteroid (if over 12 years).  Systemically very unwell or high risk of complications: immediate antibiotic.  For detailed information click on the visual summary. | First choice: **phenoxymethylpenicillin** | 500mg QDS | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng79/resources/visual-summary-pdf-4656316717) | 5 days | [Link to visual summary](https://www.nice.org.uk/guidance/ng79) |
| Penicillin allergy:  **doxycycline** (not in under 12s) OR | 200mg on day 1, then 100mg OD | 5 days |
| **clarithromycin** OR | 500mg BD |
| **erythromycin** (preferred if pregnant) | 250 to 500mg QDS or  500 to 1000mg BD |
| Second choice or first choice if systemically very unwell or high risk of complications:  **co-amoxiclav** | 500/125mg TDS | 5 days |
| Lower respiratory tract infections | | | | | | | |
| Acute exacerbation of COPD  NICE logo  Public Health England  Last updated:  Dec 2018 | | Many exacerbations are not caused by bacterial infections so will not respond to antibiotics. Consider an antibiotic, but only after considering severity of symptoms (particularly sputum colour changes and increases in volume or thickness), need for hospitalisation, previous exacerbations, hospitalisations and risk of complications, previous sputum culture and susceptibility results, and risk of resistance with repeated courses.  Some people at risk of exacerbations may have antibiotics to keep at home as part of their exacerbation action plan.  For detailed information click on the visual summary. See also the [NICE guideline on COPD in over 16s](https://www.nice.org.uk/guidance/ng115). | **First choice:**  **amoxicillin** OR | 500mg TDS (see BNF for severe infection) | - | 5 days | [Link to visual summary](https://www.nice.org.uk/guidance/ng114) |
| **doxycycline** OR | 200mg on day 1, then 100mg OD (see BNF for severe infection) | - |
| **clarithromycin** | 500mg BD | - |
| Second choice: use alternative first choice | | | |
| Alternative choice (if person at higher risk of treatment failure):  **co-amoxiclav** OR | 500/125mg TDS | - | 5 days |
| **co-trimoxazole** OR | 960mg BD | - |
| **levofloxacin** (with specialist advice if **co-amoxiclav** or **co-trimoxazole** cannot be used; consider safety issues) | 500mg OD | - |
| IV antibiotics (specialist only) | | | |
| **Acute exacerbation of bronchiectasis (non-cystic fibrosis)**  **NICE logo**  Public Health England  **Acute exacerbation of bronchiectasis (non-cystic fibrosis) cont.**  Last updated:  Dec 2018 | | Send a sputum sample for culture and susceptibility testing.  Offer an antibiotic.  When choosing an antibiotic, take account of severity of symptoms and risk of treatment failure. People who may be at higher risk of treatment failure include people who’ve had repeated courses of antibiotics, a previous sputum culture with resistant or atypical bacteria, or a higher risk of developing complications.  Course length is based on severity of bronchiectasis, exacerbation history, severity of exacerbation symptoms, previous culture and susceptibility results, and response to treatment.  Do not routinely offer antibiotic prophylaxis to prevent exacerbations.  Seek specialist advice for preventing exacerbations in people with repeated acute exacerbations. This may include a trial of antibiotic prophylaxis after a discussion of the possible benefits and harms, and the need for regular review.  *For detailed information click on the visual summary.* | First choice empirical treatment:  **amoxicillin** (preferred if pregnant) OR | 500mg TDS | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng117/resources/visual-summary-pdf-6606081325) | 7 to 14 days | [Link to visual summary](https://www.nice.org.uk/guidance/ng117/resources/visual-summary-pdf-6606081325) |
| **doxycycline** (not in under 12s) OR | 200mg on day 1, then 100mg OD |
| **clarithromycin** | 500mg BD |
| Alternative choice (if person at higher risk of treatment failure) empirical treatment:  **co-amoxiclav** OR | 500/125mg TDS | 7 to 14 days |
| levofloxacin (adults only: with specialist advice if co‑amoxiclav cannot be used; consider safety issues) OR | 500mg OD or BD |
| ciprofloxacin (children only: with specialist advice if co‑amoxiclav cannot be used; consider safety issues) | - |
| IV antibiotics (specialist only) | | | |
| When current susceptibility data available: choose antibiotics accordingly | | | |
| Acute Cough  NICE logo  Last updated:  Feb 2019 | | Some people may wish to try honey (in over 1s), the herbal medicine pelargonium (in over 12s), cough medicines containing the expectorant guaifenesin (in over 12s) or cough medicines containing cough suppressants, except codeine, (in over 12s). These self-care treatments have limited evidence for the relief of cough symptoms.  Acute cough with upper respiratory tract infection: no antibiotic.  Acute bronchitis: no routine antibiotic.  Acute cough and higher risk of complications (at face-to-face examination/remote examination): immediate or back-up antibiotic.  Acute cough and systemically very unwell (at face to face examination/remote examination): immediate antibiotic.  Higher risk of complications includes people with pre-existing comorbidity; young children born prematurely; people over 65 with 2 or more of, or over 80 with 1 or more of: hospitalisation in previous year, type 1 or 2 diabetes, history of congestive heart failure, current use of oral corticosteroids.  Do not offer a mucolytic, an oral or inhaled bronchodilator, or an oral or inhaled corticosteroid unless otherwise indicated.  *For detailed information click on the visual summary. See also the NICE guideline on* [pneumonia](https://www.nice.org.uk/guidance/cg191) *for prescribing antibiotics in adults with acute bronchitis who have had a C‑reactive protein (CRP) test (CRP<20mg/l: no routine antibiotic, CRP 20 to 100mg/l: back-up antibiotic, CRP>100mg/l: immediate antibiotic).* | Adults first choice (if indicated):  doxycycline | 200mg on day 1, then 100mg OD | - | 5 days | [Link to visual summary](https://www.nice.org.uk/guidance/ng120) |
| Adults alternative first choices:  amoxicillin (preferred if pregnant) OR | 500mg TDS | - |
| clarithromycin OR | 250mg to 500mg BD | - |
| erythromycin (preferred if pregnant) | 250mg to 500mg QDS or  500mg to 1000mg BD | - |
| **Children first choice (if indicated):**  amoxicillin | - | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng120/resources/visual-summary-pdf-6664861405) | 5 days |
| **Children alternative first choices:**  clarithromycin OR | - |
| erythromycin OR | - |
| doxycycline (not in under 12s) | - |
| NICE logo  COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community [[NG165]](https://www.nice.org.uk/guidance/ng165/chapter/4-Managing-suspected-or-confirmed-pneumonia) | | **On 23 April 2020,** NICE clarified the recommendations on antibiotic treatment for bacterial pneumonia in the community during the COVID-19 pandemic.  As COVID‑19 pneumonia is caused by a virus, antibiotics are ineffective. **Do not offer** an antibiotic for treatment or prevention of pneumonia if COVID‑19 is likely to be the cause and symptoms are mild.  Offer an oral antibiotic for treatment of pneumonia in people who can or wish to be treated in the community if the likely cause is bacterial or it is unclear whether the cause is bacterial or viral and symptoms are more concerning or they are at high risk of complications because, for example, they are older or frail, or have a pre-existing comorbidity such as immunosuppression or significant heart or lung disease (for example bronchiectasis or COPD), or have a history of severe illness following previous lung infection. | First choice  **doxycycline** (not in under 12s) | 200mg on day 1, then 100mg OD for 4 days |  | 5 Days |  |
| **Alternative:** **amoxicillin** | 500mg TDS | 5 Days |
| For choice of antibiotics in penicillin allergy, pregnancy and more severe disease, or if atypical pathogens are likely, see the normal community acquired pneumonia NICE guidance below |  |  |
| Community-acquired pneumonia  NICE logo  Public Health England  Community-acquired pneumonia cont.  Last updated: Sept 2019 | | Assess severity in adults based on clinical judgement guided by mortality risk score (CRB65 or CURB65). See the NICE guideline on [pneumonia](https://www.nice.org.uk/guidance/cg191) for full details:  low severity – CRB65 0 or CURB65 0 or 1  moderate severity – CRB65 1 or 2 or CURB65 2  high severity – CRB65 3 or 4 or CURB65 3 to 5.  Each CRB65 parameter scores one:  • Confusion (AMT<8, or new disorientation in person, place or time)  • Respiratory rate >30/min;  • BP systolic <90 or diastolic ≤ 60;  • Age > 65  Assess severity in children based on clinical judgement.  Offer an antibiotic. Start treatment as soon as possible after diagnosis, within 4 hours (within 1 hour if sepsis suspected and person meets any high-risk criteria – see the NICE guideline on [sepsis](https://www.nice.org.uk/guidance/ng51)).  When choosing an antibiotic, take account of severity, risk of complications, local antimicrobial resistance and surveillance data, recent antibiotic use and microbiological results.  \* Stop antibiotics after 5 days unless microbiological results suggest a longer course is needed or the person is not clinically stable.  For detailed information click on the visual summary. See also the NICE guideline on [pneumonia](https://www.nice.org.uk/guidance/cg191). | First choice (low severity in adults or non-severe in children): **amoxicillin** | 500mg TDS (higher doses can be used, see BNF) | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng138/resources/visual-summary-pdf-6903410941) | 5 days\* | [Link to visual summary](https://www.nice.org.uk/guidance/ng138/resources/visual-summary-pdf-6903410941) |
| Alternative first choice (low severity in adults or non-severe in children): **doxycycline** (not in under 12s) OR | 200mg on day 1, then 100mg OD |
| **clarithromycin** OR | 500mg BD |
| **erythromycin** (in pregnancy) | 500mg QDS |
| First choice (moderate severity in adults): **amoxicillin** AND (if atypical pathogens suspected) | 500mg TDS (higher doses can be used, see BNF) | - | 5 days\* |
| **clarithromycin** OR | 500mg BD | - |
| **erythromycin** (in pregnancy) | 500mg QDS | - |
| Alternative first choice (moderate severity in adults): **doxycycline** OR | 200mg on day 1, then 100mg OD | - |
| **clarithromycin** | 500mg BD | - |
| First choice (high severity in adults or severe in children): **co-amoxiclav**  AND (if atypical pathogens suspected) | 500/125mg TDS | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng138/resources/visual-summary-pdf-6903410941) | 5 days\* |
| **clarithromycin** OR | 500mg BD |
| **erythromycin** (in pregnancy) | 500mg QDS |
| Alternative first choice (high severity in adults):  **levofloxacin** (consider safety issues) | 500mg BD | - |
| IV antibiotics (specialist only) | | | |
| Urinary tract infections | | | | | | | |
| Lower urinary tract infection  NICE logo  Public Health England  Lower urinary tract infection cont.  Last updated:  Oct 2018 | | Advise paracetamol or ibuprofen for pain and to drink sufficient fluids to avoid dehydration.  Non-pregnant women: back up antibiotic (to use if no improvement in 48 hours or symptoms worsen at any time) or immediate antibiotic.  Pregnant women, men, children or young people: send midstream urine for culture and sensitivity before treatment empirically.  When considering antibiotics, take account of severity of symptoms, risk of complications, previous urine culture and susceptibility results, previous antibiotic use which may have led to resistant bacteria and local antimicrobial resistance data.  For detailed information click on the visual summary. See also the NICE guideline on [urinary tract infection in under 16s: diagnosis and management](https://www.nice.org.uk/guidance/cg54) and the Public Health England [urinary tract infection: diagnostic tools for primary care](https://www.gov.uk/government/publications/urinary-tract-infection-diagnosis).  \*Only if non-pregnant woman has failed any first-choice treatment options for in the last 1 month or risk factor for increased resistance  Risk factors for increased resistance –   * care home resident * recurrent UTI (2 in 6 months; 3 in 12 months) * hospitalisation for >7 days in the last 6 months * recent travel to country with increased resistance * previous resistant isolates, unresolving urinary symptoms | Non-pregnant women first choice:  **nitrofurantoin** (if eGFR ≥45 ml/minute) OR | 100mg m/r BD (or if unavailable 50mg QDS) | - | 3 days | [Link to visual summary](http://www.nice.org.uk/guidance/ng109) |
| **trimethoprim** (only if culture results available and susceptible) | 200mg BD | - |
| Non-pregnant women second choice: **nitrofurantoin** (if eGFR ≥45 ml/minute) OR | 100mg m/r BD (or if unavailable 50mg QDS) | - | 3 days |
| \***pivmecillinam** (a penicillin) OR | 400mg initial dose, then 200mg TDS | - | 3 days |
| \***fosfomycin** | 3g single dose sachet | - | single dose |
| Pregnant women first choice: **nitrofurantoin** (avoid at term) – if eGFR ≥45 ml/minute | 100mg m/r BD (or if unavailable 50mg QDS) | - | 7 days |
| Pregnant women second choice: **amoxicillin** (only if culture results available and susceptible) OR | 500mg TDS | - | 7 days |
| **cefalexin** | 500mg BD | - |
| Treatment of asymptomatic bacteriuria in pregnant women: choose from **nitrofurantoin** (avoid at term), **amoxicillin** or **cefalexin** based on recent culture and susceptibility results | | | |
| Men first choice:  **nitrofurantoin** (if eGFR ≥45 ml/minute) OR | 100mg m/r BD (or if unavailable 50mg QDS) | - | 7 days |  |
| **Trimethoprim**  (only if culture results available and susceptible) | 200mg BD | - |
| Men second choice: basing antibiotic choice on recent culture and susceptibility results. Consider alternative diagnoses | | | |
| Children and young people (3 months and over) first choice:  **trimethoprim** (only if culture results available and susceptible) OR | - | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng109/resources/visual-summary-pdf-6544021069) | - |
| **nitrofurantoin** (if eGFR ≥45 ml/minute) | - |
| Children and young people (3 months and over) second choice:  **nitrofurantoin** (if eGFR ≥45 ml/minute and not used as first choice) OR | - |
| **amoxicillin** (only if culture results available and susceptible) OR | - |
| **cefalexin** | - |
| Recurrent urinary tract infection  NICE logo  Public Health England  Last updated:  Oct 2018 | | First advise about behavioural and personal hygiene measures, and self-care (with D-mannose or cranberry products) to reduce the risk of UTI.  For postmenopausal women, if no improvement, consider vaginal oestrogen **(review within 12 months).**  For non-pregnant women, if no improvement, consider single-dose antibiotic prophylaxis for exposure to a trigger **(review within 6 months).**  For non-pregnant women (if no improvement or no identifiable trigger) or with specialist advice for pregnant women, men, children or young people, consider a trial of daily antibiotic prophylaxis **(review within 6 months).**  For detailed information click on the visual summary. See also the NICE guideline on [urinary tract infection in under 16s: diagnosis and management](https://www.nice.org.uk/guidance/cg54) and the Public Health England [urinary tract infection: diagnostic tools for primary care](https://www.gov.uk/government/publications/urinary-tract-infection-diagnosis). | First choice antibiotic prophylaxis: **nitrofurantoin** (avoid at term) - if eGFR  ≥45 ml/minute OR | 100mg single dose when exposed to a trigger or  50 to 100mg at night | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng112/resources/visual-summary-pdf-6544163629) | - | [Link to visual summary](http://www.nice.org.uk/guidance/ng112) |
| **trimethoprim** (avoid in pregnancy) | 200mg single dose when exposed to a trigger or  100mg at night | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng112/resources/visual-summary-pdf-6544163629) | - |
| Second choice antibiotic prophylaxis:  **amoxicillin** OR | 500mg single dose when exposed to a trigger or 250mg at night | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng112/resources/visual-summary-pdf-6544163629) | - |
| **cefalexin** | 500mg single dose when exposed to a trigger or  125mg at night | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng112/resources/visual-summary-pdf-6544163629) | - |
| Acute pyelonephritis  (upper urinary tract)  NICE logo  Public Health England  Last updated:  Oct 2018 | | Advise paracetamol (+/- low-dose weak opioid) for pain for people over 12. Send midstream urine sample for culture and susceptibility testing  Offer an antibiotic.  When prescribing antibiotics, take account of severity of symptoms, risk of complications, previous urine culture and susceptibility results, previous antibiotic use which may have led to resistant bacteria and local antimicrobial resistance data. People at higher risk of complications include those with abnormalities of the genitourinary tract or underlying disease (such as diabetes or immunosuppression).  For detailed information click on the visual summary. See also the NICE guideline on [urinary tract infection in under 16s: diagnosis and management](https://www.nice.org.uk/guidance/cg54) and the Public Health England [urinary tract infection: diagnostic tools for primary care](https://www.gov.uk/government/publications/urinary-tract-infection-diagnosis). | Non-pregnant women and men first choice:  **cefalexin** OR | 1g TDS | - | 7 to 10 days | [Link to visual summary](http://www.nice.org.uk/guidance/ng111) |
| **co-amoxiclav** (only if culture results available and susceptible) OR | 500/125mg TDS | - | 7 to 10 days |
| **trimethoprim** (only if culture results available and susceptible) OR | 200mg BD | - | 14 days |
| **ciprofloxacin** (consider safety issues) | 500mg BD | - | 7 days |
| Non-pregnant women and men IV antibiotics (click on visual summary) | | | |
| Pregnant women first choice:  **cefalexin** | 500mg BD or TDS (up to 1g to 1.5g TDS or QDS for severe infections) | - | 7 to 10 days |
| Pregnant women second choice or IV antibiotics (click on visual summary) | | | |
| Children and young people (3 months and over) first choice: **cefalexin** OR | - | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng111/resources/visual-summary-pdf-6544161037) | - |
| **co-amoxiclav** (only if culture results available and susceptible) | - |
| Children and young people (3 months and over) IV antibiotics (specialist only) | | | |
| **Catheter-associated urinary tract infection**  NICE logo  Public Health England  **Catheter-associated urinary tract infection cont.**  Last updated:  Nov 2018 | | Antibiotic treatment is not routinely needed for asymptomatic bacteriuria in people with a urinary catheter.  Consider removing or, if not possible, changing the catheter if it has been in place for more than 7 days. But do not delay antibiotic treatment if it is indicated.  Advise paracetamol for pain.  Advise drinking enough fluids to avoid dehydration.  Offer an antibiotic for a symptomatic infection.  When prescribing antibiotics, take account of severity of symptoms, risk of complications, previous urine culture and susceptibility results, previous antibiotic use which may have led to resistant bacteria and local antimicrobial resistance data.  Do not routinely offer antibiotic prophylaxis to people with a short-term or long-term catheter.  For detailed information click on the visual summary. See also the Public Health England [urinary tract infection: diagnostic tools for primary care](https://www.gov.uk/government/publications/urinary-tract-infection-diagnosis). | Non-pregnant women and men first choice if no upper UTI symptoms:  **nitrofurantoin** (if eGFR ≥45 ml/minute) OR | 100mg m/r BD (or if unavailable 50mg QDS) | - | 7 days | [Link to visual summary](https://www.nice.org.uk/guidance/ng113) |
| **trimethoprim** (if low risk of resistance) OR | 200mg BD | - |
| **amoxicillin** (only if culture results available and susceptible) | 500mg TDS | - |
| **Non-pregnant women and men second choice if no upper UTI symptoms:**  **pivmecillinam** (a penicillin) | 400mg initial dose, then 200mg TDS | - | 7 days |
| **Non-pregnant women and men first choice if upper UTI symptoms:**  **cefalexin** OR | 500mg BD or TDS (up to 1g to 1.5g TDS or QDS for severe infections) | - | 7 to 10 days |
| **co-amoxiclav** (only if culture results available and susceptible) OR | 500/125mg TDS | - |
| **trimethoprim** (only if culture results available and susceptible) OR | 200mg BD | - | 14 days |
| **ciprofloxacin** (consider safety issues) | 500mg BD | - | 7 days |
| Non-pregnant women and men IV **antibiotics** *(click on visual summary)* | | | |
| **Pregnant women first choice**:  **cefalexin** | 500mg BD or TDS (up to 1g to 1.5g TDS or QDS for severe infections) | - | 7 to 10 days |
| **Pregnant women second choice or IV antibiotics** *(click on visual summary)* | | | |
| **Children and young people (3 months and over) first choice:** **trimethoprim** (only if culture results available and susceptible) OR | - | [Link to visual summary prescribing table for children](https://www.nice.org.uk/guidance/ng113/resources/visual-summary-pdf-6599495053) | - |
| **amoxicillin** (only if culture results available and susceptible) OR | - |
| **cefalexin** OR | - |
| **co-amoxiclav** (only if culture results available and susceptible) | - |
| Children and young people (3 months and over) IV **antibiotics** (specialist only) | | | |
| Acute prostatitis  NICE logo  Public Health England  Last updated:  Oct 2018 | | Advise paracetamol (+/- low-dose weak opioid) for pain, or ibuprofen if preferred and suitable.  Offer antibiotic.  Review antibiotic treatment after 14 days and either stop antibiotics or continue for a further 14 days if needed (based on assessment of history, symptoms, clinical examination, urine and blood tests).  Quinolones achieve higher prostate levels. Admit to hospital if man has any of the following: severely ill or in acute urinary retention. Consider urgent referral if man is immunocompromised or has diabetes or had a pre-existing urological condition.  *For detailed information click on the visual summary.* | First choice (guided by susceptibilities when available):  **ciprofloxacin** (consider safety issues) OR | 500mg BD | - | 14 days then review | [Link to visual summary](http://www.nice.org.uk/guidance/ng110) |
| **ofloxacin** (consider safety issues) OR | 200mg BD | - |
| **trimethoprim** (if fluoroquinolone not appropriate; seek specialist advice) | 200mg BD | - |
| Second choice (after discussion with specialist): **levofloxacin** (consider safety issues) OR | 500mg OD | - | 14 days, then review |
| **co-trimoxazole** | 960mg BD | - |
| IV antibiotics (specialist only) | | | |
|  Meningitis | | | | | | | |
| Suspected meningococcal disease  Public Health England  Last updated:  Feb 2019 | | Transfer all patients to hospital immediately.1D  If time before hospital admission,2D,3A+ if suspected meningococcal septicaemia or non-blanching rash,2D,4D give **IV or IM** **benzylpenicillin** 1D,2D,4D as soon as possible.2D Consider **IV or IM cefotaxime** in patients who cannot be given **benzylpenicillin** Do not give IV antibiotics if there is a definite history of anaphylaxis;1D rash is not a contraindication.1D | **IV or IM benzylpenicillin** 1D,2D | Child <1 year: 300mg5D  Child 1 to 9 years: 600mg5D  Adult/child 10+ years: 1.2g5D | | Stat dose;1D  give IM, if vein cannot be accessed 1D | Not available. Access the supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| For patients who cannot be given **benzylpenicillin:**  **IV or IM cefotaxime** | Child 1 month to 11 years: 50mg/kg  Child 12 to 17 years: 1g  Adult: 1g | | Stat dose;  give IM, if vein cannot be accessed |
| Prevention of secondary case of meningitis: Only prescribe antibiotics following advice from the London Health Protection Team  **North East and North Central London Health Protection Team (NENCLHPT) contact numbers:**   * Daytime Tel: **020 3837 7084 (option 2)** * **For Out of Hours Advice**: Tel: **0151 909 1215** (between 5pm and 9am and during weekends and Bank Holidays) * Email: [necl.team@phe.gov.uk](mailto:necl.team@phe.gov.uk) ; [phe.nenclhpt@nhs.net](mailto:phe.nenclhpt@nhs.net) | | | | | | | |
| Gastrointestinal tract infections | | | | | | | |
| Oral candidiasis  Public Health England  Last updated:  Oct 2018 | | Topical azoles are more effective than topical nystatin.1A+  Oral candidiasis is rare in immunocompetent adults;2D consider undiagnosed risk factors, including HIV.2D  Use 50mg fluconazole if extensive/severe candidiasis;3D,4D if HIV or immunocompromised, use 100mg fluconazole.3D,4D | **Miconazole** oral gel1A+,4D,5A- | 2.5ml of 24mg/ml QDS (hold in mouth after food) 4D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/miconazole.html) | 7 days; continue for 7 days after resolved4D,6D | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| If not tolerated: **nystatin** suspension2D,6D,7A- | 1ml; 100,000units/ml QDS (half in each side) 2D,4D,7A- | [Link to BNF for children](https://bnfc.nice.org.uk/drug/nystatin.html) | 7 days; continue for 2 days after resolved4D |
| **fluconazole** capsules6D,7A- | 50mg/100mg OD3D,6D,8A- | [Link to BNF for children](https://bnfc.nice.org.uk/drug/fluconazole.html) | 7 to 14 days6D,7A-,8A- |
| Infectious diarrhoea  Public Health England  Last updated:  Oct 2018 | | Refer previously healthy children with acute painful or bloody diarrhoea, to exclude E. coli O157 infection.1D  Antibiotic therapy is not usually indicated unless patient is systemically unwell.2D If systemically unwell and campylobacter suspected (such as undercooked meat and abdominal pain),3D consider **clarithromycin** 250mg to 500mg BD for 5 to 7 days, if treated early (within 3 days).3D,4A+  If giardia is confirmed or suspected – **tinidazole** 2g single dose is the treatment of choice.5A+ Seek specialist advice for treatment in pregnancy  Access the supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care). | | | | | |
| Helicobacter pylori  Public Health England  See PHE quick reference guide for diagnostic advice: [PHE H. pylori](https://www.gov.uk/government/publications/helicobacter-pylori-diagnosis-and-treatment)  Last updated:  Feb 2019 | | Always test for H.pylori before giving antibiotics. Treat all positives. If negative, only retest for H.pylori if DU, GU, family history of cancer, MALToma, or if test was performed within two weeks of PPI, or four weeks of antibiotics.21B+,27C  Leave a 2-week washout period after proton pump inhibitor (PPI) use before testing for H. pylori with a carbon‑13 urea breath test (UBT) or a stool antigen test (STA), or laboratory-based serology where its performance has been locally validated  Do not test for *H pylori* in proven GORD  Do not offer eradication for GORD.3D  Do not use **clarithromycin**, **metronidazole** or **quinolone** if used in the past year for any infection.5A+,6B+,7A+  Penicillin allergy: use PPI PLUS **clarithromycin** PLUS **metronidazole**.2D If previous **clarithromycin**, use PPI PLUS bismuth salt PLUS **metronidazole** PLUS **tetracycline** hydrochloride.2D,8A-,9D  Relapse and no penicillin allergy use PPI PLUS **amoxicillin** PLUS **clarithromycin** or **metronidazole** (whichever was not used first line) 2D  Relapse and previous metronidazole and clarithromycin: use PPI PLUS **amoxicillin** PLUS either **tetracycline** OR **levofloxacin** (if **tetracycline** not tolerated).2D,7A+  Relapse and penicillin allergy (no exposure to quinolone): use PPI PLUS **metronidazole** PLUS **levofloxacin**.2D  Relapse and penicillin allergy (with exposure to quinolone): use PPI PLUS bismuth salt PLUS **metronidazole** PLUS **tetracycline**.2D  Retest for H. pylori: post DU/GU, or relapse after second-line therapy,1A+ using UBT or SAT,10A+,11A+ consider referral for endoscopy and culture.2D  **PPI** – Use either Omeprazole 20mg BD **OR** Lansoprazole 30mg BD | Always use PPI2D,3D,5A+,12A+  **First line and first relapse and no penicillin allergy**  PPI PLUS 2 antibiotics | - | [Link to BNF for children](https://bnfc.nice.org.uk/treatment-summary/proton-pump-inhibitors.html) | 7 days2D  MALToma 14 days7A+,16A+ | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| **amoxicillin**2D,6B+ PLUS | 1000mg BD14A+ | [Link to BNF for children](https://bnfc.nice.org.uk/drug/amoxicillin.html) |
| **clarithromycin**2D,6B+ OR | 500mg BD8A- | [Link to BNF for children](https://bnfc.nice.org.uk/drug/clarithromycin.html) |
| **metronidazole**2D,6B+ | 400mg BD2D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/metronidazole.html) |
| Penicillin allergy and previous clarithromycin:  PPI WITH bismuth subsalicylate PLUS 2 antibiotics | - | - |
| bismuth subsalicylate13A+ PLUS | 525mg QDS15D |
| **metronidazole**2D PLUS | 400mg BD2D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/metronidazole.html) |
| **tetracycline**2D | 500mg QDS15D |  |
| Relapse and previous metronidazole and clarithromycin:  PPI PLUS 2 antibiotics | - | - |
| **amoxicillin**2D,7A+ PLUS | 1000mg BD14A+ | [Link to BNF for children](https://bnfc.nice.org.uk/drug/amoxicillin.html) |
| **tetracycline**2D,7A+ OR | 500mg QDS15D |  |
| **levofloxacin** (if tetracycline cannot be used)2D,7A+ | 250mg BD7A+ |  |
| Third line *(specialist only)*PPI WITH | - | - | 10 days |
| bismuth subsalicylate PLUS | 525mg QDS15D | - |
| 2 antibiotics as above not previously used OR | - | - |
| **rifabutin**14A+ OR | 150mg BD | - |
| **furazolidone**17A+ | 200mg BD | - |
| Clostridium difficile  Public Health England  Last updated:  Oct 2018 | | Review need for antibiotics,1D,2D PPIs,3B- and antiperistaltic agents and discontinue use where possible.2D Mild cases (<4 episodes of stool/day) may respond without metronidazole;2D  70% respond to **metronidazole** in 5 days; 92% respond to **metronidazole** in 14 days.4B-  If no response after 7 days consider escalation to specialist  If severe (T>38.5, or WCC>15, rising creatinine, or signs/symptoms of severe colitis): 1D,2D,5A- review progress closely,1D,2D and consider hospital referral.2D 2D specialist to treat with oral **vancomycin** | Mild first episode: **metronidazole**2D,4B- | 400mg TDS1D,2D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/metronidazole.html) | 10 to 14 days1D,4B- | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| Severe, type 027 or recurrent:  oral **vancomycin**1D,2D,5A- *(specialist only)* | 125mg QDS1D,2D,5A- | [Link to BNF for children](https://bnfc.nice.org.uk/drug/vancomycin.html) | 10 to 14 days,1D,2D then taper2D |
| Recurrent or second line:  **fidaxomicin**2D,5A-  *(specialist only)* | 200mg BD5A- | - | 10 days5A- |
| **Acute diverticulitis**    Last updated: Nov 2019 | | **Acute diverticulitis and systemically well:** Consider no antibiotics, offer simple analgesia (for example paracetamol), advise to re-present if symptoms persist or worsen.  **Acute diverticulitis and systemically unwell, immunosuppressed or significant comorbidity:** offer an antibiotic.  Give oral antibiotics if person not referred to hospital for suspected complicated acute diverticulitis.  Give IV antibiotics if admitted to hospital with suspected or confirmed complicated acute diverticulitis (including diverticular abscess).  If CT-confirmed uncomplicated acute diverticulitis, review the need for antibiotics.  \* A longer course may be needed based on clinical assessment. | **First-choice (uncomplicated acute diverticulitis):**  **co-amoxiclav** | 500/125mg TDS | - | 5 days\* |  |
| **Penicillin allergy or co-amoxiclav unsuitable: cefalexin** (caution in penicillin allergy) **AND metronidazole OR** | cefalexin: 500mg BD or TDS (up to 1g to 1.5g TDS or QDS for severe infections)  metronidazole: 400mg TDS | - |
| **trimethoprim AND metronidazole** **OR** | trimethoprim: 200mg BD  metronidazole: 400mg TDS | - |
| **ciprofloxacin** (only if switching from **IV ciprofloxacin** with specialist advice; consider safety issues) **AND metronidazole** | ciprofloxacin: 500mg BD  metronidazole: 400mg TDS |  |
| **For IV antibiotics in complicated acute diverticulitis (including diverticular abscess)** *(specialist only)* | | |
| Traveller’s diarrhoea  Public Health England  Last updated:  Oct 2018 | | Prophylaxis rarely, if ever, indicated.1D Consider standby antimicrobial only for patients at high risk of severe illness,2D or visiting high-risk areas.1D,2D | Standby:  **azithromycin** | 500mg OD1D,3A+ | - | 1 to 3 days1D,2D,3A+ | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| Prophylaxis/treatment:  bismuth subsalicylate | 2 tablets QDS1D,2D | - | 2 days[1D](#Travellersdiarrhoea1),2D,4A- |
| Threadworm  Public Health England  Last updated:  Nov 2017 | | Treat all household contacts at the same time.1D Mebendazole should be advised OTC for all patients >2yrs  Advise hygiene measures for 2 weeks1D (hand hygiene;2D pants at night; morning shower, including perianal area).1D,2D Wash sleepwear, bed linen, and dust and vacuum.1D  Child <6 months, add perianal wet wiping or washes 3 hourly.1D | Child >6 months:  [**mebendazole**](http://www.medicinesinpregnancy.org/bumps/monographs/USE-OF-MEBENDAZOLE-IN-PREGNANCY/)1D,3B- (OTC for >2yrs) | 100mg stat3B- | [Link to BNF for children](https://bnf.nice.org.uk/drug/mebendazole.html#indicationsAndDoses) | 1 dose;3B- repeat in 2 weeks if persistent3B- | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| Child <6 months or pregnant (at least in first trimester):  only hygiene measure for 6 weeks1D | - | - | - |
| Genital tract infections | | | | | | | |
| STI screening  Public Health England  Last updated:  Nov 2017 | | People with risk factors should be screened for chlamydia, gonorrhoea, HIV and syphilis.1D Refer individual and partners to GUM.1D  Risk factors: <25 years; no condom use; recent/frequent change of partner; symptomatic or infected partner; area of high HIV.2B-  Access the supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care).  **(Extra care would be required in men)** | | | | | |
| Chlamydia trachomatis/ urethritis  Public Health England  Chlamydia trachomatis/ urethritis cont.  Last updated:  July 2019 | | Opportunistically screen all sexually active patients aged 15 to 24 years for chlamydia annually and on change of sexual partner.1B-  If positive, treat index case, refer to GUM and initiate partner notification, testing and treatment.2D,3A+  As single dose **azithromycin** has led to increased resistance in GU infections, **doxycycline** should be used first line for chlamydia and urethritis.4A+  Advise patient with chlamydia to abstain from sexual intercourse until **doxycycline** is completed or for 7 days after treatment with **azithromycin** (14 days after **azithromycin** started and until symptoms resolved if urethritis).3A+,4A+  If chlamydia, test for reinfection at 3 to 6 months following treatment if under 25 years; or consider if over 25 years and high risk of re‑infection.1B-,3B+, 5B-  Second line, pregnant, breastfeeding, allergy, or intolerance: **azithromycin** is most effective.6A+,7D,8A+,9A+,10D As lower cure rate in pregnancy, test for cure at least 3 weeks after end of treatment.3A+  Consider referring all patients with symptomatic urethritis to GUM as testing should include Mycoplasma genitalium and Gonorrhoea.11A-  If M.genitalium is proven, use doxycycline followed by **azithromycin** using the same dosing regimen and advise to avoid sex for 14 days after start of treatment and until symptoms have resolved.11A-,12A+ | First line:  **doxycycline**4A+,11A-,12A+ | 100mg BD4A+,11A-,12A+ | - | 7 days4A+,11A-,12A+ | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| Second line/ pregnant/breastfeeding/ allergy/intolerance: [**azithromycin**](http://www.medicinesinpregnancy.org/bumps/monographs/USE-OF-AZITHROMYCIN-IN-PREGNANCY/)4A+,11A-,12A+ | 1000mg4A+,11A-,12A+  then  500mg OD4A+,11A-,12A+ | Stat4A+,11A-,12A+  2 days4A+,11A-,12A+  (total 3 days) |
|  |  |  |
| Epididymitis  Public Health England  Last updated:  Nov 2017 | | Usually due to Gram-negative enteric bacteria in men over 35 years with low risk of STI.1A+,2D  If under 35 years or STI risk, refer to GUM.1A+,2D | **Doxycycline**1A+,2D OR | 100mg BD1A+,2D | - | 10 to 14 days1A+,2D | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| **Ofloxacin** (consider safety issues) 1A+,2D OR | 200mg BD1A+,2D | 14 days1A+,2D |
| **Ciprofloxacin** (consider safety issues) 1A+,2D | 500mg BD1A+,2D,3A+ | 10 days1A+,2D,3A+ |
| Vaginal candidiasis  Public Health England  Last updated:  Oct 2018 | | All topical and oral azoles give over 80% cure.1A+,2A+  Pregnant: avoid oral azoles, the 7-day courses are more effective than shorter ones.1A+,3D,4A+  Recurrent (>4 episodes per year):1A+ 150mg oral fluconazole every 72 hours for 3 doses induction,1A+ followed by 1 dose once a week for 6 months maintenance.1A+ | **clotrimazole**1A+,5D OR | 500mg pessary1A+ | - | Stat1A+ | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| **clotrimazole** OR | 200mg pessary | 3 nights |
| **clotrimazole**1A+ OR | 100mg pessary1A+ | 6 nights1A+ |
| **oral fluconazole**1A+,3D | 150mg1A+,3D | Stat1A+ |
| If recurrent:  **fluconazole** (induction/maintenance)1A+ | 150mg every 72 hours  THEN  150mg once a week1A+,3D | - | 3 doses  6 months1A+ |
| Bacterial vaginosis  Public Health England  Last updated:  Nov 2017 | | Oral [**metronidazole**](http://www.medicinesinpregnancy.org/bumps/monographs/USE-OF-METRONIDAZOLE-IN-PREGNANCY/) is as effective as topical treatment,1A+ and is cheaper.2D  7 days results in fewer relapses than 2g stat at 4 weeks.1A+,2D  Pregnant/breastfeeding: avoid 2g dose.3A+,4D Treating partners does not reduce relapse.5A+ | oral [**metronidazole**](http://www.medicinesinpregnancy.org/bumps/monographs/USE-OF-METRONIDAZOLE-IN-PREGNANCY/)1A+,3A+ OR | 400mg BD1A+,3A+  OR  2000mg1A+,2D | - | 5 - 7 days (NICE CKS 2018) OR  Stat2D | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| **metronidazole** 0.75% vaginal gel1A+,2D,3A+ OR | 5g applicator at night1A+,2D,3A+ | 5 nights1A+,2D,3A+ |
| **clindamycin** 2% cream1A+,2D | 5g applicator at night1A+,2D | 7 nights1A+,2D,3A+ |
| Genital herpes  Public Health England  Last updated:  Nov 2017 | | Advise: saline bathing,1A+ analgesia,1A+ or OTC topical lidocaine for pain,1A+ and discuss transmission.1A+  First episode: treat within 5 days if new lesions or systemic symptoms,1A+,2D and refer to GUM.2D  Recurrent: self-care if mild,2D or immediate short course antiviral treatment,1A+,2D or suppressive therapy if more than 6 episodes per year.1A+,2D | oral **aciclovir**1A+,2D,3A+,4A+ OR | 400mg TDS1A+,3A+ | - | 5 days1A+ | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| 200mg five times a day | 5 day (NICE CKS 2017) |
| 800mg TDS (if recurrent)1A+ | 2 days1A+ |
| **Valaciclovir** *(specialist only)* 1A+,3A+,4A+ OR | 500mg BD1A+ | 5 days1A+ |
| **Famciclovir** *(specialist only)* 1A+,4A+ | 250mg TDS1A+ | 5 days1A+ |
| 1000mg BD (if recurrent)1A+ | 1 day1A+ |
| Gonorrhoea  Public Health England  Last updated:  Feb 2019 | | Antibiotic resistance is now very high.1D,2D  Refer to GUM.3B- Test of cure is essential.2D  Use IM **ceftriaxone** if susceptibility not known prior to treatment2D.  Use **ciprofloxacin** only If susceptibility is known prior to treatment and the isolate is sensitive to ciprofloxacin at all sites of infection1D,2D | **ceftriaxone**2D OR | 1000mg IM2D | - | Stat2D | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| **ciprofloxacin**2D  (only if known to be sensitive) | 500mg2D | Stat2D |
| Trichomoniasis  Public Health England  Last updated:  Nov 2017 | | Oral treatment needed as extravaginal infection common.1D Treat partners,1D and refer to GUM for other STIs.1D  Pregnant/breastfeeding: avoid 2g single dose [**metronidazole**](http://www.medicinesinpregnancy.org/bumps/monographs/USE-OF-METRONIDAZOLE-IN-PREGNANCY/)**;**2A+,3D [**clotrimazole**](http://www.medicinesinpregnancy.org/bumps/monographs/USE-OF-CLOTRIMAZOLE-IN-PREGNANCY/)for symptom relief (not cure) if metronidazole declined.2A+,4A-,5D | **metronidazole**1A+,2A+,3D,6A+ | 400mg BD1A+,6A+ | - | 5 to 7 day1A+ | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| 2g (more adverse effects)6A+ | Stat1A+,6A+ |
| Pregnancy to treat symptoms: **clotrimazole**2A+,4A-,5D | 100mg pessary at night5D | 6 nights5D |
| Pelvic inflammatory disease  Public Health England  Last updated:  Feb 2019 | | Refer **women and sexual contacts to GUM**.1A+  Raised CRP supports diagnosis, absent pus cells in HVS smear good negative predictive value.1A+  Exclude: ectopic pregnancy, appendicitis, endometriosis, UTI, irritable bowel, complicated ovarian cyst, functional pain.  **Moxifloxacin** has greater activity against likely pathogens, but always test for gonorrhoea, chlamydia, and M. genitalium .1A+  If M. genitalium tests positive use **moxifloxacin**.1A+  [BASHH guideline for the Management of Pelvic](https://www.bashhguidelines.org/media/1217/pid-update-2019.pdf)  [Inflammatory Disease (2019 Interim Update)](https://www.bashhguidelines.org/media/1217/pid-update-2019.pdf) | First line therapy:  **ceftriaxone**1A+,3C,4C PLUS | 1000mg IM1A+,3C | - | Stat1A+,3C | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| **metronidazole**1A+,5A+ PLUS | 400mg BD1A+ | 14 days1A+ |
| **doxycycline**1A+,5A+ | 100mg BD1A+ | 14 days1A+ |
| Second line therapy:  **metronidazole**1A+,5A+ PLUS | 400mg BD1A+ | 14 days1A+ |
| **ofloxacin**1A+,2A-,5A+  OR | 400mg BD1A+,2A- | 14 days1A+ |
| **moxifloxacin** alone1A+  (first line for M. genitalium associated PID) | 400mg OD1A+ | 14 days1A+ |
| Skin and soft tissue infections | | | | | | | |
| Note: Refer to [RCGP Skin Infections](http://elearning.rcgp.org.uk/course/info.php?popup=0&id=161) online training.1D For MRSA, discuss therapy with microbiologist.1D | | | | | | | |
| Impetigo  NICE logo  Last updated:  Feb 2020 | | Localised non-bullous impetigo:  Hydrogen peroxide 1% cream (other topical antiseptics are available but no evidence for impetigo). If hydrogen peroxide unsuitable or ineffective, short-course topical antibiotic.  Widespread non-bullous impetigo:  Short-course topical or oral antibiotic. Take account of person’s preferences, practicalities of administration, previous use of topical antibiotics because antimicrobial resistance can develop rapidly with extended or repeated use, and local antimicrobial resistance data.  Bullous impetigo, systemically unwell, or high risk of complications:  Short-course oral antibiotic. Do not offer combination treatment with a topical and oral antibiotic to treat impetigo. \*5 days is appropriate for most, can be increased to 7 days based on clinical judgement.Referral to a consultant in Communicable Disease Control is required if there is a significant local outbreak (for example, in a nursing home or school). For detailed information click on the visual summary. | **Topical antiseptic:**  hydrogen peroxide | 1% BD - TDS |  | 5 days\* |  |
| First choice topical antibiotic if hydrogen peroxide unsuitable  **Fusidic Acid** | 2% ointment TDS |  |
| **Fusidic acid resistance suspected or confirmed:** **mupirocin** 2% | TDS |
| **First line oral antibiotic**  oral **flucloxacillin** | 500mg QDS |  |
| **Penicillin allergy or flucloxacillin unsuitable:** **clarithromycin** OR | 250mg BD |
| **erythromycin** (in pregnancy) | 250mg to 500mg QDS |
| **If MRSA suspected or confirmed – consult local microbiologist** | | |
| Acne  Public Health England  Last updated:  Nov 2017 | | Mild (open and closed comedones)1D or moderate (inflammatory lesions):1D  First line: self-care1D (wash with mild soap; do not scrub; avoid make-up).1D  Second line: OTC benzoyl peroxide.2D or topical retinoid e.g. adapalene 0.1% gel/cream  Third-line: add topical antibiotic,1D,3A+ or consider addition of oral antibiotic.1D  Severe (nodules and cysts):1D add oral antibiotic (for 3 months max)1D,3A+ and refer.1D,2D | Second line: topical retinoid1D,2D,3A+ OR | Thinly OD3A+ | [Link to BNF for children](https://bnfc.nice.org.uk/treatment-summary/rosacea-and-acne.html) | 6 to 8 weeks1D | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| OTC benzoyl peroxide1A-,2D,3A+,4A- | 5% cream OD-BD3A+ | [Link to BNF for children](https://bnfc.nice.org.uk/drug/benzoyl-peroxide.html) | 6 to 8 weeks1D |
| Third-line: topical **clindamycin**3A+ | 1% cream, thinly BD3A+ | [Link to BNF for children](https://bnfc.nice.org.uk/drug/clindamycin.html) | 12 weeks1A-,2D |
| If treatment failure/severe:  oral **lymecycline** **OR** | 408mg BD – 2BD | [Link to BNF for children](https://bnfc.nice.org.uk/drug/lymecycline.html) | At least 8 weeks (BNF/cBNF) |
| oral **tetracycline**1A-,3A+ OR | 500mg BD3A+ | [Link to BNF for children](https://bnfc.nice.org.uk/drug/tetracycline.html) | 6 to 12 weeks3A+ |
| oral **doxycycline**3A+,4A- | 100mg OD3A+ | [Link to BNF for children](https://bnfc.nice.org.uk/drug/doxycycline.html) | 6 to 12 weeks3A+ |
| Cold sores  Public Health England  Last updated:  Nov 2017 | | Most resolve after 5 days without treatment.1A-,2A- Topical OTC antivirals applied prodromally can reduce duration by 12 to 18 hours.1A-,2A-,3A-  If frequent, severe, and predictable triggers: consider oral prophylaxis:4D,5A+ **aciclovir** 400mg, twice daily, for 5 to 7 days.5A+,6A+  Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) | | | | | |
| PVL-SA  Public Health England  Last updated:  Nov 2017 | | Panton-Valentine leukocidin (PVL) is a toxin produced by 20.8 to 46% of S. aureus from boils/abscesses.1B+,2B+,3B- PVL strains are rare in healthy people, but severe.2B+  Suppression therapy should only be started after primary infection has resolved, as ineffective if lesions are still leaking.4D  Risk factors for PVL: recurrent skin infections;2B+ invasive infections;2B+ MSM;3B- if there is more than one case in a home or close community2B+,3B- (school children;3B- military personnel;3B- nursing home residents;3B- household contacts).3B-  Consider taking a swab of pus from the contents of the lesion if the boil or carbuncle is:  • Not responding to treatment, persistent or recurrent, to exclude atypical mycobacteria or PVL-SA.  • There are multiple lesions.  • The person: Is immunocompromised, is known to be colonized with MRSA, Has diabetes.  • If PVL-SA is suspected, this should be mentioned specifically on the laboratory form  **If positive PVL MRSA or positive *S. aureus* contact the North East and North Central London Health Protection Team (NENCLHPT) contact numbers:**   * Daytime Tel: **020 3837 7084 (option 2)** * **For Out of Hours Advice**: Tel: **0151 909 1215** (between 5pm and 9am and during weekends and Bank Holidays) * Email: [necl.team@phe.gov.uk](mailto:necl.team@phe.gov.uk) ; [phe.nenclhpt@nhs.net](mailto:phe.nenclhpt@nhs.net)   Access the supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care). | | | | | |
| Leg ulcer  NICE logo  Last updated:  Feb 2020 | | Manage any underlying conditions to promote ulcer healing.  Only offer an antibiotic when there are symptoms or signs of infection (such as redness or swelling spreading beyond the ulcer, localised warmth, increased pain or fever). Few leg ulcers are clinically infected but most are colonised by bacteria.  When prescribing antibiotics, take account of severity, risk of complications and previous antibiotic use.  For detailed information click on the visual summary. | **First-choice:** | | | |  |
| **flucloxacillin** | 500mg to 1g QDS | - | 7 days |
| Penicillin allergy or if flucloxacillin unsuitable: | | | |
| **doxycycline** OR | 200mg on day 1, then 100mg OD (can be increased to 200mg daily) | - | 7 Days |
| **clarithromycin** OR | 500mg BD |
| **erythromycin** (in pregnancy) | 500mg QDS |
| Second choice: | | | |
| **co-amoxiclav** **OR** | 500/125mg TDS | - | 7 Days |
| **co-trimoxazole** (in penicillin allergy) | 960mg BD |
| For antibiotic choices if severely unwell or MRSA suspected or confirmed, click on the visual summary | | | |
| Cellulitis and erysipelas  NICE logo  Public Health England  Last updated:  Sept 2019 | | Exclude other causes of skin redness (inflammatory reactions or non-infectious causes).  Consider marking extent of infection with a single-use surgical marker pen.  Offer an antibiotic. Take account of severity, site of infection, risk of uncommon pathogens, any microbiological results and MRSA status.  Infection around eyes or nose is more concerning because of serious intracranial complications.  \*A longer course (up to 14 days in total) may be needed but skin takes time to return to normal, and full resolution at 5 to 7 days is not expected.  Do not routinely offer antibiotics to prevent recurrent cellulitis or erysipelas.  For detailed information click on the visual summary. | First choice: | | | |  |
| **flucloxacillin** | 500mg to 1g QDS |  | 5 to 7 days\* |
| Penicillin allergy or if flucloxacillin unsuitable: | | | |
| **clarithromycin** (inc children with penicillin allergy) OR | 500mg BD |  | 5 to 7 days\* |
| **erythromycin** (in pregnancy) OR | 500mg QDS |
| **doxycycline** (adults only) OR | 200mg on day 1, then 100mg OD | - |
| **co-amoxiclav** (children only: not in penicillin allergy) | - |  |
| If infection near eyes or nose: | | | |
| **co-amoxiclav** | 500/125mg TDS |  | 7 days\* |
| If infection near eyes or nose (penicillin allergy): | | | |
| **clarithromycin** AND | 500mg BD |  | 7 days\* |
| **metronidazole** (only add in children if anaerobes suspected) | 400mg TDS |
| For alternative choice antibiotics for severe infection, suspected or confirmed MRSA infection and IV antibiotics *(specialist only)* click on the visual summary | | | |
| Eczema  Public Health England  Last updated Nov17 | | No visible signs of infection: antibiotic use (alone or with steroids)1A+ encourages resistance and does not improve healing.1A+  With visible signs of infection: use oral flucloxacillin2D or **clarithromycin**,2D or topical treatment (as in impetigo).2D  Access the supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) | | | | | |
| Diabetic foot infection  NICE logo  Diabetic foot infection cont..  Last updated:  Oct 2019 | | In diabetes, all foot wounds are likely to be colonised with bacteria. Diabetic foot infection has at least 2 of: local swelling or induration; erythema; local tenderness or pain; local warmth; purulent discharge.  Severity is classified as:  Mild: local infection with 0.5 to less than 2cm erythema  Moderate: local infection with more than 2cm erythema or involving deeper structures (such as abscess, osteomyelitis, septic arthritis or fasciitis)  Severe: local infection with signs of a systemic inflammatory response.  Start antibiotic treatment as soon as possible.  Take samples for microbiological testing before, or as close as possible to, the start of treatment  When choosing an antibiotic, take account of severity, risk of complications, previous microbiological results and antibiotic use, and patient preference.  \*A longer course (up to a further 7 days) may be needed based on clinical assessment. However, skin does take time to return to normal, and full resolution at 7 days is not expected.  Do not offer antibiotics to prevent diabetic foot infection.  For detailed information click on the visual summary. | Mild infection: first choice | | | |  |
| **flucloxacillin** | 500mg to 1g QDS | - | 7 days\* |
| Mild infection (penicillin allergy): | | | |
| **clarithromycin** OR | 500mg BD | - | 7 days\* |
| **erythromycin** (in pregnancy) OR | 500mg QDS |
| **doxycycline** | 200mg on day 1, then 100mg OD (can be increased to 200mg daily) |
| For antibiotic choices for moderate or severe infection, infections where Pseudomonas aeruginosa or MRSA is suspected or confirmed, and IV antibiotics *(specialist only)* click on the visual summary | | | |
| Scabies  Public Health England  Last updated:  Oct 2018 | | First choice OTC permethrin: Treat whole body from ear/chin downwards,1D,2D and under nails.1D,2D  If using permethrin and patient is under 2 years, elderly or immunosuppressed, or if treating with malathion: also treat face and scalp.1D,2D  Home/sexual contacts: treat within 24 hours.1D | OTC **permethrin** (>2yrs) 1D,2D,3A+ | 5% cream1D,2D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/permethrin.html) | 2 applications, 1-week apart1D | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| Permethrin allergy:  **malathion**1D | 0.5% aqueous liquid1D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/malathion.html) |
| Bites  Public Health England  Last updated:  July 2019 | | Human: thorough irrigation is important.1A+,2D Antibiotic prophylaxis is advised.1A+,2D,3D Assess risk of tetanus, rabies,1A+ HIV, and hepatitis B and C.3D  Cat: always give prophylaxis.1A+,3D  Dog: give prophylaxis if: puncture wound;1A+,3D bite to hand, foot, face, joint, tendon, or ligament;1A+ immunocompromised; cirrhotic; asplenic; or presence of prosthetic valve/joint.2D,4A+  Penicillin allergy: Review all at 24 and 48 hours,3D as not all pathogens are covered.2D,3 | Prophylaxis/treatment all: **co-amoxiclav**2D,3D | 375mg to 625mg TDS3D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/co-amoxiclav.html) | 7 days3D | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| Human bite + penicillin allergy:  **metronidazole**3D,4A+ AND | 400mg TDS2D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/metronidazole.html) | 7 days3D |
| **clarithromycin**3D,4A+ | 250mg to 500mg BD2D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/clarithromycin.html) |
| Animal + penicillin allergy:  **metronidazole**3D,4A+ AND | 400mg TDS2D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/metronidazole.html) | 7 days3D |
| **doxycycline**3D | 100mg BD2D |
| Insect bites and stings  NICE logo  Last updated:  Sept 2020 | | An insect bite or sting often causes a small, red lump on the skin, which may be painful and itchy. Secondary bacterial infection is unlikely; it is unclear which causative organisms are most common. **Do not offer an antibiotic if there are no symptoms or signs of infection.**  With rapid-onset skin reactions likely to be inflammatory or allergic reactions, most bites and stings will not need antibiotics.  The guideline notes people may wish to consider oral antihistamines (OTC) to help relieve itching (which may last up to 10 days), and some antihistamines cause sedation, which might help at night.  For bites and stings where there is a sign of an infection, antibiotic treatment recommendations in the NICE guideline on cellulitis and erysipelas should be followed, or the guidance on Lyme disease if there is a known or suspected tick bite. | | | | |  |
| Mastitis  Public Health England  Last updated:  Nov 2017 | | S. aureus is the most common infecting pathogen.1D Suspect if woman has: a painful breast;2D fever and/or general malaise;2D a tender, red breast.2D  Breastfeeding: oral antibiotics are appropriate, where indicated.2D,3A+ Women should continue feeding,1D,2D including from the affected breast.2D | **For lactating woman:**  **flucloxacillin**2D | 500mg QDS2D | - | 10 to 14 days2D | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| If penicillin allergy: **erythromycin**2D OR | 250mg to 500mg QDS2D |
| **clarithromycin**2D | 500mg BD2D |
| **For non-lactating woman** (NICE CKS)**:**  **co-amoxiclav** | 625mg TDS |
| If penicillin allergy (NICE CKS)**: Metronidazole** **AND** | 500mg TDS |
| **Erythromycin OR** | 250mg to 500mg QDS |
| **clarithromycin** | 500mg BD |
| Dermatophyte infection: skin  Public Health England  Last updated:  Feb 2019 | | **Dermatophyte infection: skin**  Including: Tinea corporis (ringworm) Tinea pedis (athlete's foot), Tinea cruris (jock itch) Tinea faciei (facial ringworm), Tinea capitis (scalp ringworm)  Most cases: use **terbinafine** as fungicidal, treatment time shorter and more effective than with fungistatic **imidazoles** or **undecenoates** 1D,2A+ If candida possible, use imidazole.4D  If intractable, or scalp: send skin scrapings,1D and if infection confirmed: use oral **terbinafine**1D,3A+,4D or **itraconazole**.2A+,3A+,5D  Scalp: oral therapy,6D and discuss with specialist.1D | topical **terbinafine**3A+,4D OR | 1% OD to BD2A+ | [Link to BNF for children](https://bnfc.nice.org.uk/drug/terbinafine.html) | 1 to 4 weeks3A+ | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| topical **clotrimazole** 2A+,3A+ | 1% OD to BD2A+ | [Link to BNF for children](https://bnfc.nice.org.uk/treatment-summary/skin-infections.html) | 4 to 6 weeks2A+,3A+ |
| Alternative in athlete’s foot:  topical **undecenoates**2A+ (such as Mycota®)2A+ | OD to BD2A+ | [Link to BNF for children](https://bnfc.nice.org.uk/drug/undecenoic-acid-with-zinc-undecenoate.html) |
| Dermatophyte infection: nail  Public Health England  Last updated:  Oct 2018 | | Take nail clippings;1D start therapy only if infection is confirmed.1D Oral **terbinafine** is more effective than oral azole.1D,2A+,3A+,4D Liver reactions 0.1 to 1% with oral antifungals.3A+ If candida or non-dermatophyte infection is confirmed, use oral **itraconazole**.1D,3A+,4D Topical nail lacquer is not as effective.1D,5A+,6D  To prevent recurrence: apply weekly 1% topical antifungal cream to entire toe area.6D  Children: seek specialist advice.4D | First line:  **terbinafine**1D,2A+,3A+,4D,6D | 250mg OD1D,2A+,6D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/terbinafine.html) | Fingers: 6 weeks1D,6D to 3 months (NICE CKS)  Toes: 12 weeks1D,6D to 6 months (NICE CKS) | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| Second line:  **itraconazole**1D,3A+,4D,6D | 200mg BD1D,4D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/itraconazole.html) | 1 week repeated after 21 days  Fingers: 2 courses1D  Toes: 3 courses1D |
| Stop treatment when continual, new, healthy, proximal nail growth.6D | | | |
| Varicella zoster/ chickenpox  Herpes zoster/ shingles  Public Health England  Last updated:  Oct 2018 | | Pregnant/immunocompromised/ neonate/Breastfeeding: seek urgent specialist advice.1D  Chickenpox: consider **aciclovir**2A+,3A+,4D if: onset of rash <24 hours,3A+ and 1 of the following: >14 years of age;4D severe pain;4D dense/oral rash;4D,5B+ taking steroids;4D smoker.4D,5B+  Give paracetamol for pain relief.6C  Shingles: treat if >50 years7A+,8D (PHN rare if <50 years)9B+ and within 72 hours of rash,10A+ or if 1 of the following: active ophthalmic;11D Ramsey Hunt;4D eczema;4D non-truncal involvement;8D moderate or severe pain;8D moderate or severe rash.5B+,8D  Shingles treatment if not within 72 hours: consider starting antiviral drug up to 1 week after rash onset,12B+ if high risk of severe shingles12B+ or continued vesicle formation;4D older age;7A+,8D,12B+ immunocompromised;4D or severe pain.7D,11B+ | First line for chicken pox and shingles: **aciclovir**3A+,7A+,10A+,13B+,14A-,15A+ | 800mg 5 times daily16A- | [Link to BNF for children](https://bnfc.nice.org.uk/drug/aciclovir.html) | 7 days14A-,16A- | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| Second line for shingles if poor compliance:  not for children:  **famciclovir**8D,14A-, 16A- *(specialist only)* OR | 250mg to 500mg TDS15A+ OR  750mg BD15A+ | - |
| **valaciclovir**8D,10A+,14A- *(specialist only)* | 1g TDS14A- | [Link to BNF for children](https://bnfc.nice.org.uk/drug/valaciclovir.html) |
| Tick bites  (Lyme disease)  Public Health England  Tick bites  (Lyme disease) cont.  Last updated:  Feb 2020 | | Treatment: Treat erythema migrans empirically; serology is often negative early in infection.1D  For other suspected Lyme disease such as neuroborreliosis (CN palsy, radiculopathy) seek advice.1D  [**See NICE NG95** for full treatment doses/information](https://www.nice.org.uk/guidance/ng95/chapter/Recommendations#management) | Treatment  **doxycycline**1D | 100mg BD1D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/doxycycline.html) | 21 days1D | [**See NICE NG95**](https://www.nice.org.uk/guidance/ng95/chapter/Recommendations#management) |
| Alternative**:** **amoxicillin**1D | 1,000mg TDS1D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/amoxicillin.html) |
| **Be aware that:**   * the bacteria that cause Lyme disease are transmitted by the bite of an infected tick * ticks are mainly found in grassy and wooded areas, including urban gardens and parks * tick bites may not always be noticed * infected ticks are found throughout the UK and Ireland, and although some areas appear to have a higher prevalence of infected ticks, prevalence data are incomplete   particularly high-risk areas are the South of England and Scottish Highlands but infection can occur in many areas   * Lyme disease may be more prevalent in parts of central, eastern and northern Europe (including Scandinavia) and parts of Asia, the US and Canada.   **Be aware that:**   * most tick bites do not transmit Lyme disease and that prompt, correct removal of the tick reduces the risk of transmission.   **Give people advice about:**   * where ticks are commonly found (such as grassy and wooded areas, including urban gardens and parks) * the importance of prompt, correct tick removal and how to do this (see the Public Health England website for [information on removing ticks](https://www.gov.uk/government/publications/tick-bite-risks-and-prevention-of-lyme-disease)) * covering exposed skin and using insect repellents that protect against ticks * how to check themselves and their children for ticks on the skin * sources of information on Lyme disease, such as [Public Health England](https://www.gov.uk/government/collections/lyme-disease-guidance-data-and-analysis), and organisations providing information and support, such as patient charities. | | | | | |
| MRSA Decolonisation | | MRSA decolonisation is not routinely recommended for patients in the community unless clinically indicated. Conditions where MRSA eradication may be considered include:   * Preparation for an elective procedure where patient is identified as positive for MRSA colonisation * Management of a high-risk wound as advised by the microbiology/infection team * Management of indwelling devices as advised by the microbiology/infection team  |  |  |  | | --- | --- | --- | | **Trust** | **Recommended Decolonisation Regimen** | **Comments** | | **Bart’s Health NHS Trust** | Please refer to full guidance on microguide app  <http://microguide.horizonsp.co.uk/viewer/barts/adult> | Click on healthcare - associated infections section then click MRSA | | **Barking,Havering and Redbridge University Trust** | Please refer to full guidance on microguide app  <https://viewer.microguide.global/bhrhospitals/adult> | Click on healthcare - associated infections section | | **Homerton University Hospital NHSFT** | Please refer to guidance on microguide app  <https://viewer.microguide.global/huh/adult> | See “Infection Prevention and Control” section. Note: The Microguide contains the in-patient decolonisation protocol only. Liaise with Infection Control to decide appropriateness and discuss if alternative protocol required. |   Advice on antibiotic treatment for clinically infected wounds in MRSA colonised patients can be obtained from the hospital microbiology team.  For further information refer to each individual Trust guidelines. | | | | | |
| Eye infections | | | | | | | |
| Conjunctivitis  Public Health England  Last updated:  July 2019 | First line: bath/clean eyelids with cotton wool dipped in sterile saline or boiled (cooled) water, to remove crusting.1D Advice to avoid the use of contact lenses.  Treat only if severe,2A+ as most cases are viral3D or self-limiting.2A+  Bacterial conjunctivitis: usually unilateral and also self-limiting.2A+,3D It is characterised by red eye with mucopurulent, not watery discharge.3D 65% and 74% resolve on placebo by days 5 and 7.4A-,5A+ Third line: **fusidic acid** as it has less Gram-negative activity.6A-,7D | | Second line:  OTC (>2yrs):  **chloramphenicol** 1D,2A+,4A-,5A+  0.5% eye drop1D,2A+  OR  1% ointment1D,5A+ | Eye drops: 2 hourly for 2 days,1D,2A+ then reduce frequency1D to 3 to 4 times daily.1D Eye ointment: 3 to 4 times daily or once daily at night if using antibiotic eye drops during the day.1D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/chloramphenicol.html) | 48 hours after  resolution2A+,7D | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| Third line:  **fusidic acid** 1% gel2A+,5A+,6A- | BD1D,7D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/fusidic-acid.html) |
| Blepharitis  Public Health England  Last updated:  Nov 2017 | First line: lid hygiene1D,2A+ for symptom control,1D including: warm compresses;1D,2A+ lid massage and scrubs;1D gentle washing;1D avoiding cosmetics.1D  Second line: OTC topical antibiotics if hygiene measures are ineffective after 2 weeks.1D,3A+  Signs of meibomian gland dysfunction,3D or acne rosacea:3D consider oral antibiotics.1D | | Second line:  topical OTC (>2yrs) **chloramphenicol**1D,2A+,3A- | 1% ointment BD2A+,3D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/chloramphenicol.html) | 6-week trial3D | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| Third line:  oral **oxytetracycline**1D,3D OR | 500mg BD3D  250mg BD3D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/oxytetracycline.html) | 4 weeks (initial)3D  8 weeks (maint)3D |
| oral **doxycycline**1D,2A+,3D | 100mg OD3D  50mg OD3D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/doxycycline.html) | 4 weeks (initial)3D  8 weeks (maint)3D |
| Suspected dental infections in primary care (outside dental settings) | | | | | | | |
| Derived from the[**Scottish Dental Clinical Effectiveness Programme (SDCEP) 2013 Guidelines**](http://www.sdcep.org.uk/wp-content/uploads/2013/03/SDCEP+MADP+Guidance+March+2013.pdf)**. This guidance is not designed to be a definitive guide to oral conditions, as GPs should not be involved in dental treatment. Patients presenting to non-dental primary care services with dental problems should be directed to their regular dentist, or if this is not possible, to the NHS 111 service (in England), who will be able to provided details of how to access emergency dental care.** | | | | | | | |
| Note: Antibiotics do not cure toothache.1D First‑line treatment is with paracetamol1D and/or ibuprofen;1D codeine is not effective for toothache.1D | | | | | | | |
| Mucosal ulceration and inflammation (simple gingivitis)  Public Health England  Last updated:  Nov 2017 | Temporary pain and swelling relief can be attained with OTC saline mouthwash (½ tsp salt in warm water)1D. Use antiseptic mouthwash if more severe,1D and if pain limits oral hygiene to treat or prevent secondary infection.1D,2A- The primary cause for mucosal ulceration or inflammation (aphthous ulcers;1D oral lichen planus;1D herpes simplex infection;1D oral cancer)1D needs to be evaluated and treated.1D | | OTC **Chlorhexidine** 0.12 to 0.2%1D, 2A-,3A+,4A+ (do not use within 30 minutes of toothpaste)1D  OR | Rinse with 10 ml1D for 1-minute BD | [Link to BNF for children](https://bnfc.nice.org.uk/treatment-summary/mouthwashes-and-other-preparations-for-oropharyngeal-use.html)  [Link to BNF for children](https://bnfc.nice.org.uk/medicinal-forms/chlorhexidine.html) | Always spit out after use.1D  Use until lesions resolve1D or less pain allows for oral hygiene1D | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| OTC hydrogen peroxide 6%5A- 1D | Dilute 15ml in ½ glass warm water and rinse for 2 to 3 minutes BD/TDS1D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/hydrogen-peroxide.html) |
| Acute necrotising ulcerative gingivitis  Public Health England  Last updated:  Nov 2017 | Refer to dentist for scaling and hygiene advice.1D,2D  Antiseptic mouthwash if pain limits oral hygiene.1D  Commence **metronidazole** if systemic signs and symptoms.1D,2D,3B-,4B+,5A- | | OTC **chlorhexidine** 0.12 to 0.2% (do not use within 30 minutes of toothpaste)1D OR | Rinse with 10 ml1D for 1-minute BD | [Link to BNF for children](https://bnfc.nice.org.uk/drug/chlorhexidine.html) | Until pain allows for oral hygiene6D | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| OTC hydrogen peroxide 6%1D | Dilute 15ml in ½ glass warm water and rinse for 2 to 3 minutes BD/TDS1D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/hydrogen-peroxide.html) |
| **metronidazole**1D,3B-,4B+,5A- | 400mg TDS1D,2D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/metronidazole.html) | 3 days1D,2D |
| Pericoronitis  Public Health England  Last updated:  Nov 2017 | Refer to dentist for irrigation and debridement.1D  If persistent swelling or systemic symptoms,1D use **metronidazole**1D,2A+,3B+ or amoxicillin.1D,3B+  Use antiseptic mouthwash if pain and trismus limit oral hygiene.1D | | **metronidazole**1D,2A+,3B+ OR | 400mg TDS1D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/metronidazole.html) | 3 days1D,2A+ | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| **amoxicillin**1D,3B+ | 500mg TDS1D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/amoxicillin.html) | 3 days1D |
| **chlorhexidine** 0.2% (do not use within 30 minutes of toothpaste)1D OR | Rinse with 10 ml1D for 1-minute BD | [Link to BNF for children](https://bnfc.nice.org.uk/drug/chlorhexidine.html) | Until less pain allows for oral hygiene1D |
| hydrogen peroxide 6%1D | Dilute 15ml in ½ glass warm water and rinse for 2 to 3 minutes BD/TDS1D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/hydrogen-peroxide.html) |
| Dental abscess  Public Health England  Last updated:  Oct 2018 | Regular analgesia should be the first option1A+ until a dentist can be seen for urgent drainage,1A+,2B-,3A+ as repeated courses of antibiotics for abscesses are not appropriate.1A+,4A+ Repeated antibiotics alone, without drainage, are ineffective in preventing the spread of infection.1A+,5C Antibiotics are only recommended if there are signs of severe infection,3A+ systemic symptoms,1A+,2B-,4A+ or a high risk of complications.1A+ Patients with severe odontogenic infections (cellulitis,1A+,3A+ plus signs of sepsis;3A+,4A+ difficulty in swallowing;6D impending airway obstruction)6D should be referred urgently for hospital admission to protect airway,6D for surgical drainage3A+ and for IV antibiotics.3A+ The empirical use of **cephalosporins**,6D **co-amoxiclav,**6D **clarithromycin,**6D and **clindamycin**6D do not offer any advantage for most dental patients,6D and should only be used if there is no response to first‑line drugs.6D | | | | | | |
| If pus is present, refer for drainage,1A+,2B- tooth extraction,2B- or root canal.2B-  Send pus for investigation.1A+  If spreading infection1A+ (lymph node involvement1A+,4A+ or systemic signs,1A+,2B-,4A+ that is, fever1A+ or malaise)4A+ ADD metronidazole.6D,7B+  Use **clarithromycin** in true penicillin allergy6D and, if severe, refer to hospital.3A+,6D | | **amoxicillin**6D,8B+,9C,10B+ OR | 500mg to 1000mg TDS6D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/amoxicillin.html) | Up to 5 days; 6D,10B+ review at 3 days9C,10B+ | Not available. Access supporting evidence and rationales on the [PHE website](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care) |
| **phenoxymethylpenicillin**11B- | 500mg to 1000mg QDS6D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/phenoxymethylpenicillin.html) |
| **metronidazole**6D,8B+,9C | 400mg TDS6D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/metronidazole.html) |
| Penicillin allergy: **clarithromycin**6D | 500mg BD6D | [Link to BNF for children](https://bnfc.nice.org.uk/drug/clarithromycin.html) |

**Information for Patients**

1. **NHS website -** [**complete guide to conditions, symptoms and treatments, including what to do and when to get help.**](https://www.nhs.uk/conditions/)
2. **[Target RCGP Treating your infection leaflet](https://www.rcgp.org.uk/clinical-and-research/target-antibiotics-toolkit/~/media/2E1292605D174B318A5302223B04C175.ashx)**
3. [**The TARGET Treating Your Infection (TYI):**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/leaflets-to-share-with-patients.aspx)

[Urinary Tract Infection TYI-UTI leaflet](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/leaflets-to-share-with-patients.aspx)



The TYI-UTI patient Information leaflet has been designed to be used with women who are experiencing urinary symptoms suggesting non complicated UTIs.

This leaflet supports implementation of recommendations in the NICE guidelines on [**processes for antimicrobial stewardship**](https://www.nice.org.uk/guidance/ng15), [**behaviour change for antimicrobial stewardship**](https://www.nice.org.uk/guidance/ng63) and [**antibiotic prescribing for respiratory tract infections**](https://www.nice.org.uk/guidance/cg69).

[**TYI-UTI patient leaflet V22 (Word)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/A4F5EDC6652E429E90E053024187208F.ashx)  
[**TYI-UTI patient leaflet V22 (PDF)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/85AAD1D4DDEF455A85E0416C3BB714AE.ashx)  
[**TYI-UTI fully referenced leaflet V22 (PDF)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/8DC538A6A0C14F02B70D7C866785B161.ashx)  
[**TYI-UTI leaflet translation - Welsh V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/8AE768A448A44184ABD0C6AF64F7384F.ashx)  
[**TYI-UTI leaflet user guide V2.1 (Word)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/78BAB8F1B36B47388E8BD290711171A7.ashx)  
[**TYI-UTI leaflet SystmOne upload instructions**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/0BA9C1807DE043969F06C45B41805CE7.ashx)

**TYI-UTI leaflet translations**

|  |  |  |  |
| --- | --- | --- | --- |
| * [**Albanian - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/4CE9FBA2F8094117A9DE4A10DD5B2E22.ashx) * [**Arabic - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/6EF88616324F4C7E97483437AC749409.ashx) * [**Bengali - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/0A7B3694A45A4FFCA572D84B4F93EC31.ashx) * [**Cantonese - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/91B04201EE9A4B0C86AB7CA78D9B8356.ashx) * [**Farsi- TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/15CC15ABF44D4AAC985211EEEB8E8765.ashx) * [**French - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/650F169C1211406BBD26241DEB24F373.ashx) | * [**Greek - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/26F49DA109B54547875F0320C2B71CAD.ashx) * [**Gujarati - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/F6369319BD714CC09190127983DA83B3.ashx) * [**Hindi- TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/285274EA297B4090BAB631C9830E8814.ashx) * [**Hungarian - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/42F3104591EF4975BAF40FFF6B827A2A.ashx) * [**Kurdish - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/51A08203FCA142D599B86F2FF024A80D.ashx) * [**Lithuanian - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/D26CFFA552A14171A1842A54E7075B4E.ashx) | * [**Mandarin - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/11270C64739A4EFFA1F4638FD759AE7D.ashx) * [**Polish - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/4F57983381484C3CAA069E4A2344DBDB.ashx) * [**Portuguese - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/FFA7E708CEF246258CD5FD58BDC0BC42.ashx) * [**Punjabi - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/1272D820C06E4E22BABFC30977F9BD6E.ashx) * [**Romanian - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/1C8345E99D1C459C8D96CA142C1270B1.ashx) * [**Somali - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/0675BDC38DBD4A848F00C222EC19228F.ashx) | * [**Spanish TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/A74BC1810C404523B3D35F02EFF07CE3.ashx) * [**Swahili - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/15607A6D90B4483FACD816EFBE8C2011.ashx) * [**Tigrinya - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/ABF96459EB824EDD9697FA9F1F45AEDB.ashx) * [**Turkish - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/1A712F09B3D6441A9B058CFF53890FEA.ashx) * [**Urdu - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/95E6CBBA8BD54CCDA7DD8FC1F2463B1D.ashx) * [**Welsh - TYI-UTI V22**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/8AE768A448A44184ABD0C6AF64F7384F.ashx) |

[Urinary Tract Infection for Older Adults leaflet](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/leaflets-to-share-with-patients.aspx)


  
The older adult UTI patient Information leaflet has been designed to be used with older adults who are at risk of UTI, experiencing urinary symptoms or have been diagnosed with UTI. This leaflet accurately reflects recommendations in the NICE guidelines on [**antimicrobial stewardship**](https://www.nice.org.uk/guidance/ng15) and [**urinary tract infections**](https://www.nice.org.uk/guidance/ng109).

[**TYI-UTI leaflet for older adults V1.2 (Word)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/22C7A1B941F54956A58532E90E8F24A5.ashx)  
[**TYI-UTI leaflet for older adults V1.2 (PDF)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/30AFCD12F74F4EA3B456ECF9B21D0F80.ashx)   
[**TYI-UTI Leaflet for older adults - user guide V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/223810138C8343E69F1C2B994B02AF17.ashx)  
[**TYI-UTI information leaflet for older adults (fully referenced)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/E24EA65E5D904338B146555A1B90D91A.ashx)  
[**TYI-UTI leaflet for older adults - Welsh V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/441254B50BAD476CB0EB1E860B3088CE.ashx)

**TYI-UTI older adults leaflet translations**

|  |  |  |  |
| --- | --- | --- | --- |
| * [**Albanian - TYI-UTI  V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/7501F2D8036F44D29BDA2395D99FA9FD.ashx) * [**Arabic - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/5CBC2D3D0F68476396C6217692D444FA.ashx) * [**Bengali - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/94C1265A1D094DBD9716C7150C2F86ED.ashx) * [**Cantonese - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/61505571D1AB49FA82F973A7EB204D13.ashx) * [**Farsi - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/75145B05C43245EC861ABF2904ED873C.ashx) * [**French - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/5B85C5F4C2944D19B076FFB5F6B36F3C.ashx) | * [**Greek - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/CFC87199FD7C439A86ACD0054183EB01.ashx) * [**Gujarati - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/44F583AB0E144763B51FC8F17D1D2467.ashx) * [**Hindi - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/C74B666C370E41A686FE5426936A0150.ashx) * [**Hungarian - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/42C100AAE90045D2972609354F64B674.ashx) * [**Kurdish - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/DE2BC81FC2044CC998E4636B4BC812DC.ashx) * [**Lithuanian - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/9B3876863F8C491DAEFD4C81DF7471AC.ashx) | * [**Mandarin - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/A0B849C9DD2448F885347A55A249B68C.ashx) * [**Polish - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/07EA789197664F01BBD9DCF8B0A94E98.ashx) * [**Portuguese - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/DA75DD9B89E04A4DBD97B45D00774B25.ashx) * [**Punjabi - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/F3966B1B55C14899A314C7680F07B827.ashx) * [**Romanian - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/96A1B9E1467B4C8682AEA14F663144CA.ashx) * [**Somali - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/237503B7801A47508C0D227197B0B461.ashx) | * [**Swahili - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/7704756AFD634BC39FC4A8D63C2831C4.ashx) * [**Spanish - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/30859CF664664CA5B7114421515F917E.ashx) * [**Tigrinya - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/27D14A7D7ADD4BB4B2D02172CA664C2B.ashx) * [**Turkish - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/BD5B86C5AE304EEDB8212DDF94E9D6E7.ashx) * [**Urdu - TYI-UTI V1.2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/701258F210E6481A8F0E38F6B31E9313.ashx) |

[Respiratory Tract Infection TYI-RTI Leaflet](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/leaflets-to-share-with-patients.aspx)



The TYI-RTI patient Information leaflet has been designed to be used with patients who are experiencing self limiting RTIs.

This leaflet supports implementation of recommendations in the NICE guidelines on [**processes for antimicrobial stewardship**](https://www.nice.org.uk/guidance/ng15), [**behaviour change for antimicrobial stewardship**](https://www.nice.org.uk/guidance/ng63) and [**antibiotic prescribing for respiratory tract infections.**](https://www.nice.org.uk/guidance/cg69)

[**TYI-RTI patient leaflet – V8.1 (Word)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/12B04B8E4D8A466A9D8AB8A4D6E75DDF.ashx)  
[**TYI-RTI patient leaflet – V8.1 (PDF)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/9ACFD17AEAD84E32BD8EBB3DC042C543.ashx)  
[**TYI-RTI fully referenced leaflet V8.1 (PDF)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/F61EB0032C8146FB9EB0FE43F9735F77.ashx)  
[**TYI-RTI fully referenced leaflet – V8.1 (Word)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/50EA907E128642B6AEFE0237158332EA.ashx)  
[**TYI-RTI leaflet for GPs user guide V4.3**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/2DD3E3FC39A440EAAD591B63855B4766.ashx)  
[**TYI-RTI leafet EMIS system upload instructions**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/94BF700D782943739AEC58005455392F.ashx)  
[**TYI-RTI leaflet SystemOne upload instructions**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/43808FFCA83D4179AFB509E7362543DC.ashx)

**TYI-RTI leaflet translations**

|  |  |  |  |
| --- | --- | --- | --- |
| * [**Albanian - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/7F8D7B640B6248749E26994DF5F1A4AB.ashx) * [**Arabic - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/15D7FA28EFEF48DD9B26147103357671.ashx) * [**Bengali - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/A7DDCD2B1D0D4076905A0DD4C310B1F5.ashx) * [**Cantonese - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/4668B47EA8F144A2A0D7451BDA55FC09.ashx) * [**Farsi -TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/9B4C8FCBC3D8459E91CA52C19ABEDE4F.ashx) * [**French - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/6DC505B2F5B24723964466939957F5E3.ashx) | * [**Greek TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/9F00F52321FF489DA55087395A9EA907.ashx) * [**Gujarati - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/7C99C65644A2462F9C630A045644AAB3.ashx) * [**Hindi - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/2D9DD8EFF731455E83F8CD351FF4E49E.ashx) * [**Hungarian - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/6CAA10431AD14F699F3AAC40DF63ABCD.ashx) * [**Italian - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/BC4B6388C2064F0586D0406321940DF7.ashx) * [**Kurdish Sorani - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/08C40CEC12ED4401B2710B68503021CF.ashx) * [**Lithuanian - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/FA654463EB5F4B3D9D421331D1F4CD28.ashx) | * [**Mandarin - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/45F311124CEF42758DF0C4D6796BC7BC.ashx) * [**Polish - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/64EF1221F21D49BFBE4F9796C8573ACE.ashx) * [**Portuguese - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/5FDF3B8734024817AA9BD74483BD44DB.ashx) * [**Punjabi - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/9415FC94B86B492C95616A77A3EA1610.ashx) * [**Romanian - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/491735F37A4F478E9528AC1A36E8DBB2.ashx) * [**Somali -TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/E6B62A1159E7472DA80655CEB74D7BA4.ashx) | * [**Spanish - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/451F7FDAE89F4FD1A28333FE601CDC83.ashx) * [**Swahili - TY-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/8FDEA9D4D9534EA89A0256100EE182FC.ashx) * [**Tigrinya - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/D6993069A7E4493A81698E6EDF0282E5.ashx) * [**Turkish - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/AED8E966575847F0823713A37EB1D7B0.ashx) * [**Welsh - TYI-RTI V8.1**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/56E2C38F7B3D4A5BA0A6564B1C6A49B4.ashx) |

[Respiratory Tract Infection TYI-RTI Leaflet for other settings](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/leaflets-to-share-with-patients.aspx)

**Treating your infection - Respiratory Tract Infection Pictorial leaflet**



**TYI-RTI pictorial leaflet – simplified version**


[**Pictorial Managing Your Infection TYI-RTI leaflet V2 (Word)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/2AA03C3380B4490199CE18E6DA8C2809.ashx)  
[**Pictorial Managing Your Infection TYI-RTI leaflet V2 (PDF)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/F5ACA152D9374B82B99CE78943062250.ashx)  
[**Pictorial Managing Your Infection TYI-RTI leaflet - WELSH V2 (PDF)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/01AAB0D45D4A40E19603FEE1310F7E2C.ashx)  
[**Pictorial Managing Your Infection TYI-RTI leaflet - Condensed version V3 (PDF)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/384030D2E6754D0C90477C27C44CF7B1.ashx)  
[**Pictorial Managing Your Infection TYI-RTI leaflet User Guide V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/25656DED1CC541C1A60E0721469A5702.ashx)

**TYI-RTI leaflet for other clinical settings**

* [**TYI-RTI leaflet for OOH Clinics (Word)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/11F3CA02C99746EEA12702CBAD9A41A3.ashx)
* [**TYI-RTI leaflet for OOH Clinics (PDF)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/1912B8172ED2478B95FD372DF629D0A2.ashx)
* [**TYI-RTI leaflet for out of hours clinics - Welsh V8.1 (PDF)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/EEA30A8991DA4375B7F30E11775A1CD3.ashx)
* [**TYI-RTI leaflet for community pharmacies (Word)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/88CA490970F3496EA348A53C3FEA8FD6.ashx)
* [**TYI-RTI leaflet for community pharmacies (PDF)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/12992E5D00BE4709BB7A3112749B0279.ashx)
* [**TYI-RTI leaflet for community pharmacies Welsh V8 (PDF)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/F3185A5E9F084B528FBA755D283A21FB.ashx)

**TYI-RTI pictorial leaflet translations**

|  |  |  |  |
| --- | --- | --- | --- |
| * [**Albanian - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/43F1660B2ACB434992E97DFD654AD85C.ashx) * [**Arabic - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/55EB467C95FB4FCC83E302407A74F6E5.ashx) * [**Bengali - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/F916494409BA42008EC9F630A2ABC5F4.ashx) * [**Cantonese - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/FC91264EC96C43B99A7484E2DC06D029.ashx) * [**Farsi - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/2E2E49389FA94C1E8052DAE6B2D8FCA4.ashx) * [**French - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/235FEA89458645898BED710EB9B5D7C3.ashx) | * [**Greek - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/9140951A00B447FD9D3475A9FF332A01.ashx) * [**Gujarati - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/E141DB7B926C426388A4A2A0116B5A79.ashx) * [**Hindi - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/755EE864B3ED4C9091C807028F059984.ashx) * [**Hungarian - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/3F8186C911E847A9B5106A8559DE4B16.ashx) * [**Kurdish- TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/9B1C7E9E0007407DB3D5D8E321AF4057.ashx) * [**Lithuanian -TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/244860B71D5346329A49CF8ED399B8D5.ashx) | * [**Mandarin - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/DFCF51AF1F914DC5900C4B004CE1CDFB.ashx) * [**Polish - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/2F3F640266A4466AA3597B103474EC1D.ashx) * [**Portuguese - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/9782C0238EAE4C5185B7EE0E93FB00E6.ashx) * [**Punjabi - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/CADC62C13FCE479F837C93A859A55493.ashx) * [**Romanian - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/DF27AF420C484A69B6733A73FDF83747.ashx) * [**Somali - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/3B56D8A3134747459634A99CE33DF5BA.ashx) | * [**Spanish - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/8525339E0C75488BA4C362B7DB615504.ashx) * [**Swahili - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/AFAF41AFC4C04B3AA500B3B887E607E2.ashx) * [**Tigrinya - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/2102D944847A4C1CAFEDD87202138482.ashx) * [**Turkish - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/B2422669654B4C6FB3B40A9AE424F573.ashx) * [**Urdu - TYI-RTI Pictorial V2**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/01A06792F4604D35BCD55544BA7B1AFA.ashx) |

1. **[](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/EA495AFF6E9944009A26D22E8FCD02A4.ashx)**[**Other useful leaflets (not developed by TARGET)**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/leaflets-to-share-with-patients.aspx)

**Public Health England Stool collection leaflet (click on the picture to download the leaflet)**

**[](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/AB3CCC61F14746448E5CCDAD4684376F.ashx)**The stool collection leaflet is a step-by-step guide illustrating how to collect a stool sample for microbiological examination.


**Antibiotic guardian leaflet (click on the image to download the leaflet)**

Part of the dental antimicrobial stewardship toolkit for primary care, this leaflet highlights why antibiotics don't cure toothache and provides safety netting advice.

**[](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/B9466CCBE2D4480BB3855077123F4BF7.ashx)When should I worry? Booklet for parents and carers (click on the image to download the booklet). For other languages please visit the** [**When Should I Worry**](http://www.whenshouldiworry.com/) **website.**

The 'When Should I Worry?' booklet provides information for parents about the management of respiratory tract infections such as coughs, colds, sore throats and ear aches in children. It is designed to be shared in consultations.

**Caring for children with coughs leaflet (click on the image to download the leaflet)**

**[](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/03D8F882081F425CA00D4A6006075087.ashx)[](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/F44016DD19504EB2B6E79B76F0E873A4.ashx)**This leaflet was co-created by a diverse group of parents and University of Bristol researchers.  It contains information addressing the four most common parental concerns for children with RTI with cough and safety-netting advice based on NICE guidelines.  The leaflet was created under a creative commons licence (attribution) which means they can be used, reproduced and distributed by anyone as long as they are clearly attributed in any report or publication and cited as: Cabral, C. Ingram, J. Redmond, N. Horwood, J. Blair, P. Hollinghurst, S. Hay, A. Lucas P. 2016, ‘Caring for children with coughs: Information and advice for parents’. University of Bristol, Bristol. Foreign language translation of this leaflet are available from the [**University of Bristol**](https://child-cough.bristol.ac.uk/) website.

**Get well soon without antibiotics leaflet (click on the image to download the leaflet)**

This leaflet, produced by the Department of Health, explains the need to get the right treatment for common illnesses such as colds and coughs without encouraging antibiotic resistance. It is available in different languages and is suitable for distribution in waiting areas.

**[](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/AF47E0EEFB2C4AEEB7F41199B86D30CE.ashx)**

**Antibiotics Don’t Cure Toothache (click on the image to download the leaflet)**

Part of the dental antimicrobial stewardship toolkit for primary care, this leaflet highlights why antibiotics don't cure toothache and provides safety netting advice.

**Self-care forum fact sheets**

The Self-Care Forum is dedicated to helping people take care of themselves and as such, have created a series of self-care fact sheets for common ailments which aim to help clinicians and patients discuss issues around self-care during consultation and especially how to handle the symptoms in the future.

* [**Self-care forum fact sheet - Fever in children**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/E1006F7125A244E4B8BAA50550BF506C.ashx) [PDF]
* [**Self-care forum fact sheet - Cough**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/4414952464A543C4A19BC7C19B36CE90.ashx) [PDF]
* [**Self-care forum fact sheet - Acne**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/D40BFEC8FE9443DC947052D47990E90E.ashx) [PDF]
* [**Self-care forum fact sheet - Sore throat**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/EAFB08724ACA42F5ACEEE1D45F532FC7.ashx) [PDF]
* [**Self-care forum fact sheet -**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/AF26F39615074198A45A029A65820D13.ashx) [PDF]
* [**Self-care forum fact sheet - Common cold**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/30AC02292E4D439C9CA8596061D6DA19.ashx) [PDF]
* [**Self-care forum fact sheet - Urine symptoms in men**](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit/-/media/E114F3C60F154A7992AF9A0559B14AEF.ashx) [PDF]
* [**Self-care forum - Home care is best poster for GP waiting area**](http://www.selfcareforum.org/wp-content/uploads/2011/07/Poster_fin.pdf)[PDF]

**ELHCP Care Home Hydration and UTI Resources**



* UTI assessment tool for care home staff



* Hydration guide for care homes



* Hydration poster



* All about urine leaflet



* Monthly Structured Drinks Rounds Chart

|  |  |
| --- | --- |
| **Notification of Diseases** | |
| Registered medical practitioners (RMPs) have a statutory duty to notify suspected cases of certain infectious diseases (listed below).  These can be notified via the North East and North Central London Health Protection Team (NENCLHPT):   * Daytime Tel: **020 3837 7084 (option 2)** * **For Out of Hours Advice**: Tel: **0151 909 1215** (between 5pm and 9am and during weekends and Bank Holidays) * Email: [necl.team@phe.gov.uk](mailto:necl.team@phe.gov.uk) ; [phe.nenclhpt@nhs.net](mailto:phe.nenclhpt@nhs.net) | |
| **Notifiable diseases** | |
| Acute encephalitis  Acute infectious hepatitis  Acute meningitis  Acute poliomyelitis  Anthrax  Botulism  Brucellosis  Cholera  Diphtheria  Enteric fever (typhoid or paratyphoid fever)  Food poisoning  Haemolytic uraemic syndrome (HUS)  Infectious bloody diarrhoea  Invasive group A streptococcal disease  Legionnaires’ disease  Leprosy | Malaria  Measles  Meningococcal septicaemia  Mumps  Plague  Rabies  Rubella  Severe Acute Respiratory Syndrome (SARS)  Scarlet fever  Smallpox  Tetanus  Tuberculosis  Typhus  Viral haemorrhagic fever (VHF)  Whooping cough  Yellow fever |

**Other References**

1. [Public Health England – Guidance for managing common infections, including upper and lower respiratory, and urinary tract infections. Latest review August 2020](https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care)
2. [National Institute for health and Care Excellence (NICE) Antimicrobial prescribing guidelines](https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/antimicrobial-prescribing-guidelines)
3. [NICE Clinical Knowledge Summaries](https://cks.nice.org.uk/)
4. [Royal College of General Practitioners Sexually Transmitted Infections](https://www.rcgp.org.uk/clinical-and-research/resources/a-to-z-clinical-resources/sexually-transmitted-infections-in-primary-care.aspx)
5. [British Association for Sexual Health and HIV (BASHH)](https://www.bashh.org/guidelines)

**Other useful links**

1. [TARGET Antibiotics Toolkit](https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit.aspx)
2. [UK Teratology Service/Best Use of Medicines in Pregnancy](http://www.uktis.org/)
3. [Antibiotic Guardian](http://antibioticguardian.com/) - The Antibiotic Guardian campaign encourages the public and health professionals to pledge to use antibiotics more responsibly.
4. [Bristol University resources on caring for children with coughs](http://child-cough.bristol.ac.uk/) - This website was created by a collaboration of researchers and parents who talked to lots of parents about what information they wanted to know when their child had a cough.
5. [The British Infection Association (BIA)](https://www.britishinfection.org/) - The BIA aims to promote the science and practice of medicine in relation to infection, to support all infection specialists and trainees, and to further research into infection.
6. [The British Society for Antimicrobial Chemotherapy (BSAC)](http://www.bsac.org.uk/) - BSAC exists to facilitate the acquisition and dissemination of knowledge in the field of antimicrobial chemotherapy.
7. [e-Bug](http://www.e-bug.eu/) - operated by Public Health England, is a free microbiology, hygiene and antibiotic educational resource for junior (9-11 years) and senior (12-15 years) school students, young adults (15-18 years) and community groups across Europe.
8. [European Centre for Disease Prevention and Control (ECDC)](https://ecdc.europa.eu/en) - A number of initiatives are taking place across Europe to spread the messages on the risks associated with inappropriate use of antibiotics and how to take antibiotics responsibly.
9. [Health Education England (HEE) Antimicrobial Resistance](https://www.youtube.com/watch?v=oMnU6g2djm4) -  The HEE antimicrobial resistance animation intends to assist prescribers when they are faced with somebody who incorrectly feels they should be prescribed an antibiotic.
10. [Medicines for Children](http://www.medicinesforchildren.org.uk/) - The Medicines for Children website provides information for parents and carers about giving medicines to children, written and reviewed by doctors, pharmacists, parents and carers.
11. [Patient.info](https://patient.info/) - This website has useful patient information leaflets about all minor illnesses and self-management options.
12. [RCGP Sepsis Toolkit](https://www.rcgp.org.uk/clinical-and-research/toolkits/sepsis-toolkit.aspx) - The Sepsis toolkit provides a collection of tools, knowledge, and current guidance to support the identifying and appropriate management of patients with sepsis.
13. [Scottish Antimicrobial Prescribing Group (SAPG)](http://www.sapg.scot/)- SAPG is a national clinical multi-disciplinary forum and its primary objective is to co-ordinate and deliver a national framework for antimicrobial stewardship to enhance the quality of antimicrobial prescribing and management in Scotland.
14. [Treat yourself better](http://www.treatyourselfbetter.co.uk/) - The treat yourself better website has a symptom checker for cold and flu as well as the message that antibiotics do not work these symptoms.
15. [World Antibiotic Awareness Week (WAAW)](http://www.who.int/campaigns/world-antibiotic-awareness-week/en/) and [European Antibiotic Awareness Day (EAAD)](http://antibiotic.ecdc.europa.eu/en/EAAD/Pages/Home.aspx) - WAAW/EAAD  takes place during November each year and aims to increase awareness of global antibiotic resistance and to encourage best practices among the public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance.

**Key Contacts Guideline Review Group**

|  |  |  |  |
| --- | --- | --- | --- |
| **CCG** | **Email contact** | | **Contact Number** |
| BHR CCGs | [Bhrmedicines.management@nhs.net](mailto:Bhrmedicines.management@nhs.net) | | 0203 182 3133 |
| City and Hackney CCG | [cahccg.cityandhackneymedicines@nhs.net](mailto:cahccg.cityandhackneymedicines@nhs.net) | | 0203 816 3224 |
| Newham CCG | [NEWCCG.medicinesmanagement@nhs.net](mailto:NEWCCG.medicinesmanagement@nhs.net) | | 0203 688 2353 |
| Tower Hamlets CCG | [THCCG.medicinesoptimisation@nhs.net](mailto:THCCG.medicinesoptimisation@nhs.net) | | 020 3688 2556 |
| Waltham Forest CCG | [WFCCG.medicinesoptimisation@nhs.net](mailto:WFCCG.medicinesoptimisation@nhs.net) | | 020 3688 2652 |
| **Microbiology team contact** | | **Contact details** | |
| Barking, Havering and Redbridge University NHS Trust | | GP Microbiologist via switchboard at Queens Telephone: 01708 435000 | |
| Barts Health NHS Trust | | Tower Hamlets GP phone 07710920866,  WX GP enquiries WXH, bleep 422,  NUH GP enquiries 07887856174 | |
| Homerton University Hospital NHS Foundation Trust | | Microbiology: air-call through switchboard Antimicrobial pharmacist: bleep 209.  HUH switch: 0208 510 5555 | |

For further information please contact a member of the CCG based medicines management/optimisation teams

|  |  |
| --- | --- |
| **Name** | **Title** |
| Dr Albert J Mifsud | Consultant Public Health Microbiologist for South East London Public Health England London Public Health Laboratory |
| Dr Mark Melzer | Consultant in Microbiology / Infectious Diseases, Barts Health |
| Dr Katherine Wood | Consultant Microbiologist, HuHFT |
| Dr Alleyna Claxton | Microbiology Consultant HUHFT |
| Dr Sandra Lacey | Consultant Microbiologist, BHRuT |
| Manisha Madhani | Antimicrobial Pharmacist, BHRuT |
| Rachel Leff | Lead Pharmacist for Antimicrobials and Infection Control, Barts Health |
| Dr Sarah Hall | GP Medicines Optimisation Lead Tower Hamlets CCG |
| Sanjay Patel | Deputy Chief Pharmacist, BHR CCGs |
| Safia Pheerunggee | Senior Prescribing Advisor, Medicines Optimisation Team, WEL CCGs (Tower Hamlets) |
| Sibel Ihsan | Senior Prescribing Advisor, Medicines Optimisation Team, WEL CCGs (Waltham Forest and Newham) |
| Sagal Hashi | Joint Formulary Pharmacist, Medicines Management, C&H CCG |
| Kamaljit Takhar | Deputy Chief Pharmacist CHS, NELFT |
| Reshma Ali | BHR CCGs / NEL AMRSG Administrator |

**Document version control**

|  |  |  |  |
| --- | --- | --- | --- |
| **Version** | **Date** | **Editor** | **Details of update** |
| 1.0 | July 2020 | Reshma Ali/ Sanjay Patel (BHR CCGs) | Formatted previous infection guide and incorporated with summary table from managing common infections produced by NICE and Public Health England (PHE) information |
| 1.1 - 1.2 | Oct 2020 | Sanjay Patel (BHR CCGs) | Updated following comments from NEL AMRSG Members |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |